












David Cameron Wilkinson 
 
Adelaide Medical School 



















I would like to thank the many people who have helped me over the years. First, my 
supervisors: Leonie Heilbronn, Ian Chapman and Guy Ludbrook. Leonie Heilbronn and 
Ian Chapman have also been my co-investigators and I thank them for their patience and 
guidance. My special thanks go to Leonie’s laboratory team whose assistance has been 
invaluable.  
 
Thanks to John Lippmann for his support in general and his assistance in constructing the 
final document.  
 
Thanks to the Nurses and Technicians of the Hyperbaric Medicine Unit of the Royal 





















TABLE OF CONTENTS 
Page 
Title page …………………………………………………………… i 
Declaration …………………………………………………………… iii 
Acknowledgement …………………………………………………………… iv 
Contents …………………………………………………………… v 
Published papers …………………………………………………………… vii 
Abstract …………………………………………………………… viii 
Introduction …………………………………………………………… 1 
Chapter 1 Diabetes, insulin resistance, inflammation and hyperbaric 
oxygen - a literature review (unpublished) 
3 
Chapter 2 a. Authorship statement
b. Publication #1: Hyperbaric oxygen therapy improves
peripheral insulin sensitivity in humans
23 
25 
Chapter 3 a. Introduction
b. Authorship statement
c. Publication #2:  Hyperbaric oxygen therapy increases
insulin sensitivity in overweight men with and




Chapter 4 a. Introduction
b. Authorship statement
c. Publication #3:  Assessment of insulin sensitivity
















Chapter 5 a. Introduction 
b. Authorship statement 
c. Inflammatory cytokine production and adipose tissue 






Chapter 6 a. Introduction 
b. Authorship statement 
c. Publication #4:  Hyperbaric oxygen but not 
hyperbaric air increases insulin sensitivity in men 











The candidate was the principal author of the following publications in peer-reviewed 
journals which are submitted as part of this thesis: 
 
Wilkinson D, Chapman IM, Heilbronn LK. Hyperbaric oxygen therapy improves 
peripheral insulin sensitivity in humans. Diabet Med. 2012;29(8):986-9. doi: 
10.1111/j.1464-5491.2012.03587.x. PubMed PMID: 22269009. 
 
Wilkinson D, Nolting M, Mahadi MK, Chapman I, Heilbronn L. Hyperbaric oxygen 
therapy increases insulin sensitivity in overweight men with and without type 2 diabetes. 
Diving Hyperb Med. 2015;45(1):30-6. PubMed PMID: 25964036. 
 
Wilkinson D, Szekely S, Gue B, Tam CS, Chapman I, Heilbronn LK. Assessment of 
Insulin Sensitivity during Hyperbaric Oxygen Therapy. Diving Hyperb Med.  (accepted 
for publication 18 March 2020). 
 
Wilkinson DC, Chapman IM, Heilbronn LK. Hyperbaric oxygen but not hyperbaric air 
increases insulin sensitivity in men with type 2 diabetes mellitus. Diving Hyperb Med. 










Obesity is associated with a chronic low grade inflammatory state and the development of 
insulin resistance and diabetes, while hyperbaric oxygen therapy (HBOT) has 
demonstrated anti-inflammatory properties. But it was the observation that people with 
diabetes were susceptible to a fall in blood glucose levels during HBOT that led to an 
investigation of insulin sensitivity. 
  
Methods 
Five human studies were reported in four publications. Four studies used the 
hyperinsulinaemic euglycaemic glucose clamp and one used a frequently sampled 
intravenous glucose tolerance test (FSIGT) to investigate insulin sensitivity during 
HBOT. Studies recruited men who were overweight or obese, with and without diabetes. 
Blood samples for inflammatory cytokines and adipose tissue biopsies for gene 
expression were taken to investigate possible mechanisms of action. 
 
Results 
A total of sixty-two men were investigated by glucose clamp and nine by FSIGT. All four 
glucose clamp studies showed significant within-group increases in insulin sensitivity 
following exposure to HBOT. First, in a group of patients with (n=5) and without 
diabetes (n=5) referred for clinical HBOT, there was a 37% increase during the third 
HBOT and 41% increase during the thirtieth HBOT. Next, in a group of men who were 
overweight or obese, we found a 29% increase in men without diabetes (n=11) and 57% 
increase in those with diabetes (n=8) during the third HBOT. Further, the effect was still 
measurable in the first 30 minutes after exit from the hyperbaric chamber. Pre and post-
HBOT testing found reductions in serum TNF-α and MCP-1 while IL-6 increased. Next, 
in a group of men who were overweight or obese but without diabetes (n=9), we found a 
significant 23% increase during the first HBOT intervention. There was a significant 
increase in serum IL-6 after HBOT but no change in TNF-α or MCP-1. The final glucose 
clamp study randomised men to either HBOT (n=13) or hyperbaric air (n=11) and found 
a significant between group difference with a 26% increase in insulin sensitivity during 
HBOT but no significant change in hyperbaric air. The FSIGT study performed the 





overweight or obese and without diabetes (n=9) during the third HBOT and 24-hours later 
but found no changes from baseline.  
 
Conclusions 
The glucose clamp technique identified an acute increase in insulin sensitivity during 
HBOT. The effect could be seen in those without diabetes which suggests it is a 
physiological response to HBOT. Further research is encouraged into this insulin-
sensitising effect of HBOT as it could open new therapeutic pathways for glucose 
regulation.  No change to insulin sensitivity was seen in hyperbaric air; although it was a 
very modest exposure this may be relevant to people in other hyperbaric environments 
such as diving. The response of serum inflammatory cytokines to HBOT was inconsistent 
however two studies that showed increased insulin sensitivity during HBOT together with 























The reader may be assisted by a few words to explain the layout of this thesis and the 
reasoning that created it. When this journey began, the observation that people with 
diabetes were at risk of significant falls in their blood glucose level during clinical use of 
Hyperbaric Oxygen Therapy (HBOT) had been made in several publications. All 
hyperbaric facilities had protocols in place to monitor the blood glucose level of anyone 
with diabetes before they entered the chamber and food was provided to those with low or 
borderline readings prior to commencing HBOT. However, there appeared to have been 
no serious attempt to investigate why this occurred. I was attracted to this question. 
 
I initially discussed strategies to investigate this as a pilot study in patients referred for 
HBOT. I sought advice from an Endocrinologist; he helped me with the technical 
requirements of a hyperinsulinaemic euglycaemic glucose clamp and later became my 
principal supervisor. It became apparent during this pilot study that HBOT was having an 
influence on the glucose infusion rate during the glucose clamp technique and a more 
comprehensive study design was required. I felt that if I was to undertake further clinical 
studies in this topic, I should structure this investigation as a formal program towards a 
higher degree by research with the University of Adelaide. 
 
The pilot study was completed and published early in my candidature (Chapter 2). The 
literature review (Chapter 1) was written on the completion of this study and was 
influenced by the study findings at that point in time. The literature review was not 
written with a view to publication. With specialist medical training in Anaesthesia and 
Hyperbaric Medicine, the literature review was an opportunity for me to understand 
diabetes and the intracellular glucose transport pathway in much greater detail than I ever 
had before. The literature review also provided a section on HBOT to orientate the reader 
who was not familiar with this field of medicine, as well as a discussion about the actions 
of HBOT, particularly in regard to evidence for an anti-inflammatory action. This 
intersected with the considerable evidence for inflammatory cytokines released from 
adipose tissue driving a chronic low grade inflammatory state that has been linked to the 





developed, the association of an anti-inflammatory action of HBOT with an insulin-
sensitising effect of HBOT has become less clear. 
 
I have not revised the literature review in the intervening years. I regard the literature 
review (Chapter 1) as a primer for the focus of our thinking at the time and I have 
followed this directly with the published first study (Chapter 2). Thereafter, I have 
inserted a short introduction before each publication to provide some contextual 











Diabetes, insulin resistance, inflammation and hyperbaric oxygen 
A literature review 
Diabetes is a significant and increasing burden not just on the health system but 
ultimately the entire society for both developed and developing nations. In 2012 it was 
estimated that there were 22.3 million people in the US with the diagnosis of diabetes, 
approximately 7% of the population
1
. This has increased from an estimated 17.5 million 
in 2007. In 2012, the cost of health care for diabetes and associated lost productivity was 
estimated at US$245 billion, an increase of 41% from 2007. In Australia there are 
approximately 1.8 million people with diabetes and by 2031 it is estimated that 3.3 
million Australians will have type 2 diabetes mellitus (T2DM)
2
. Government health 
budgets around Australia spend Aus$6 billion a year on diabetes without considering 
personal costs or lost productivity. On a global perspective, health expenditure on 
diabetes was estimated at US$376 billion in 2010 and almost 4 million deaths in the 20-
79 age group were attributed to diabetes-related causes. 
Type 1 diabetes mellitus (T1DM) and T2DM are the two major forms of this disease. 
T1DM is an auto-immune disease with destruction of the β-cells of the pancreatic islets 
resulting in reduced or absent insulin secretion. It tends to occur in childhood or 
adolescence and accounts for about 10% of people with diabetes. T2DM accounts for 
approximately 90% of cases and is characterised by reduced tissue responsiveness to the 
actions of insulin together with β-cell dysfunction which reduces the capacity of the 
pancreas to secrete sufficient insulin. There is a multifactorial genetic component to 
T2DM however it is also strongly influenced by the environment, particularly diet and 
lifestyle factors. 
The relative impairment of the action of insulin on target tissues, notably muscle and 
liver, defines insulin resistance. The inverse of insulin resistance is termed insulin 
sensitivity. The onset of insulin resistance in target tissues elicits a compensatory 
response from the pancreas with an increase in insulin secretion. Insulin secretion can 
increase four to five-fold and β-cell mass can increase by 50% to augment the stimulus 
required to maintain normal blood glucose levels
3
. Insulin sensitivity can vary throughout 
life and insulin resistance has been observed physiologically during puberty, pregnancy 
4 
 
and with normal ageing. Increased insulin sensitivity can be seen with increased physical 
activity.  
For insulin resistance to progress to diabetes, β-cell dysfunction is required. A 
combination of genetic and environmental factors can render individuals susceptible to β-
cell changes which result in a diminished capacity to secrete insulin. Progressively, 
euglycaemia will be replaced by impaired glucose tolerance. With further reduction in 
insulin secretion, hyperglycaemia and clinical diabetes can eventually occur. Not 
everyone with insulin resistance will develop diabetes however insulin resistance is the 
best predictor of those likely to develop diabetes in the future 
4
.  
The epidemic in diabetes is paralleled by an epidemic in obesity. The US-based Centers 
for Disease Control and Prevention (CDC) estimated that the proportion of the US 
population that are obese (BMI≥30kg/m2) was 18% in 1998, 25% in 2006 and 35% in 
2009. In 2009, 17% of youth were considered obese. The financial burden of obesity 
consumed almost 10% of all medical spending in 2008, around US$147 billion
5
. In 
Australia, adult prevalence of those overweight (25≤BMI<30) and obese has increased 
from 56% in 1995, to 61% in 2007 and just over 63% in 2011 (ABS). For 2008, the total 
costs of obesity including medical costs, lost productivity and carers cost was estimated at 
Aus$58 billion.  
Chronic inflammation 
Obesity has a strong association with both insulin resistance and the development of 
T2DM. Obesity-related insulin resistance is associated with a chronic inflammatory state 
6
. Physiologically, we understand inflammation to be a short-term adaptive response to 
injury and infection by both the metabolic and immune systems. Obesity produces a 
sustained metabolic and immune response which shares many of the same chemical 
mediators as classical inflammation. The consequences of this prolonged inflammatory 
state may lead to the development of a cluster of metabolic diseases, or so-called 
metabolic syndrome – insulin resistance, T2DM, dyslipidaemias, hypertension and 
accelerated cardiovascular disease. The CDC estimates that 20% of the adult population 
in the US has the metabolic syndrome.  
There is an abundance of evidence linking obesity with chronic inflammation and insulin 
resistance. The first link was published in 1993 when the inflammatory cytokine, tumour 
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necrosis factor(TNF)-α was shown to be overexpressed in the adipose tissue of obese 
mice 
7
. When a TNF-α receptor blocker was given to these mice the insulin resistance 
was reversed, requiring 2-3 times the glucose infusion rate during hyperinsulinaemic 
euglycaemic clamp studies. This resistance predominantly affected peripheral glucose 
utilisation as opposed to hepatic glucose output. Another study showed that knockout 
TNF-α mice do not develop insulin resistance despite obesity
8
. Overexpression of TNF-α 
has been identified in the adipose tissue of obese humans and weight loss led to a 
reduction in TNF-α
9, 10
. Overexpression of TNF-α has also been identified in the muscle 
of obese humans
11
. Infusion of TNF-α induces insulin resistance in humans
12
 specifically 
at the level of the skeletal muscle
13
.  
Adipose tissue comprises adipocytes plus a stromal tissue portion including connective 
tissue, preadipocytes, blood vessels and macrophages. Adipose tissue from obese animals 
and humans differs from that in lean subjects with infiltration by macrophages. It is 
estimated that fat tissue of lean humans contains about 10% macrophages but in obese 
humans it can contain up to 40% macrophages
14
. Almost all of the over-expressed TNF-α 




So a picture of obesity emerges with an increase in fat tissue mass being associated with 
macrophage infiltration and activation leading to up regulation of TNF-α production and 
a sustained inflammatory response
17
. Other local effects may include TNF-α triggering 
the conversion of preadipocytes into macrophages with the expression of further 
inflammatory cytokines
15
.  Cytokines released into the systemic circulation can then lead 
to the development of insulin resistance particularly at the level of skeletal muscle. 
Furthermore, it has also become apparent that TNF-α is not the only inflammatory 
cytokine released in obesity but includes monocyte chemmoattractant protein-1 (MCP-1), 
and several members of the interleukin (IL) family. On the flip side, anti-inflammatory 
cytokine production including adiponectin may be reduced in obese individuals and 
promote insulin resistance.  
The pro-inflammatory cytokine, MCP-1 is secreted by a range of cells including 
adipocytes, macrophages and vascular endothelial cells. It is a potent attractant for 
monocytes and macrophages and MCP-1 expression in adipose tissue is increased in the 
setting of obesity
14, 15
. Mice rendered obese by a high-fat diet and transgenic MCP-1 mice 
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demonstrate macrophage infiltration of fat tissue and systemic insulin resistance by clamp 
studies
18, 19
. In another study using transgenic MCP1 mice, insulin resistance was 
associated with increased expression of TNF-α and Il-6 in adipose tissue
20
. Chronic 
administration of MCP-1 led to insulin resistance together with macrophage infiltration in 
mice while acute MCP-1 administration caused insulin resistance without macrophage 
infiltration. This suggests that MCP-1 may have a direct effect on insulin signalling that is 
independent of macrophage activity
21
. 
IL-6 has traditionally been considered a pro-inflammatory cytokine however emerging 
evidence suggests its role is far more complicated. IL6 is produced by many diverse cell 
types although one third of basal IL-6 secretion comes from macrophages within adipose 
tissue
6, 14, 22
 and mostly from visceral rather than subcutaneous adipose tissue
16, 23
. IL-6 
levels are increased with normal ageing in the absence of disease; it is responsive to sex 
hormones with actions on the menstrual cycle and spermatogenesis
24
 and it has CNS 
interactions in relation to psychological stress, fatigue and sleep
25
. Even in the context of 
insulin response it appears to display both pro- and anti-inflammatory effects and is now 
considered a pleiotropic cytokine. The pro-inflammatory role for IL-6 is supported by 
obese women who have increased serum levels of IL-6 also show reduced insulin 
sensitivity as measured by the fasting insulin resistance index
26
. The degree of insulin 
resistance was better predicted by the IL-6 level than by other cytokines such as TNF-α. 
Weight loss led to a reduction in IL-6 level together with an improvement in the insulin 
response without a significant change in TNF-α. In another study, human obesity was 
associated with increased IL-6 in adipose tissue and serum however it was serum IL-6 
that had the closest relationship with reduced insulin sensitivity as measured by 
intravenous glucose tolerance test
27
. A more complex role for IL-6 is suggested by the 
finding that exercise is an insulin sensitiser
28
 and is associated with the release of IL-6 
from muscle where serum concentrations can increase by up to 100-fold
29
. Also, acute 
infusion of IL-6 in humans led to increased insulin sensitivity measured by 
hyperinsulinaemic euglycaemic clamp
30
. In another clamp study, infusion of IL-6 showed 
no change in insulin sensitivity together with no increased gene expression of IL-18, 
another pro-inflammatory cytokine linked to insulin resistance
12
. A further study has 
suggested IL-6 may have differing effects in different tissues, showing that while IL-6 





IL-1 is a pro-inflammatory cytokine with two subtypes; IL-1α and IL-1β. They have 
similar but not identical actions however both have been shown to interfere with insulin 
signalling using in vitro models
32-34
. IL-1 is produced at sites of inflammation together 
with TNF-α and they act synergistically
35
. IL-1β has been demonstrated to be particularly 
detrimental to pancreatic islet β-cells
36
. IL-1 receptor antagonist (IL-1ra) is a member of 
the IL-1 family, produced mainly by adipocytes and binds to the IL-1 receptor 
antagonising its action
37
. There is a balance between IL-1 and IL-1ra activity. Levels of 
IL-1ra are increased in human obesity, reduced by weight loss and are related to insulin 
resistance as measured by the insulin resistance index
38
. Use of analogues of IL-1ra in 
people with T2DM has resulted in lower glycosylated haemoglobin levels, improved β-
cell secretory function but no change in insulin sensitivity by clamp
39
.  
IL-18 is a pro-inflammatory cytokine and member of the IL-1 family. IL-18 plasma levels 
are elevated in people with T2DM compared to those without diabetes and IL-18 levels 
correlate with homeostasis model assessment of insulin resistance (HOMA-IR)
40
. Another 
study found plasma IL-18 is increased in obesity, reduced with weight loss and was 
correlated with HOMA -IR
41
.   In a population study of 955 people, serum IL-18 levels 




This is not an exhaustive list of players however this soup of cytokines already suggests a 
more complicated, inter-related process is in play. The weight of evidence for TNF-α 
having a major role is evident although human studies using drugs to block TNF-α action 
have not been so conclusive
43, 44
. IL-6 can have pro- and anti-inflammatory actions yet 
some of the studies mentioned show IL-6 levels are a better predictor for insulin 
resistance than other cytokines like TNF-α. Certainly there are differences in the effects 
of short-term infusions of IL-6 compared to chronic infusions. Cytokines are known to 
work in networks - the effect of any particular chemical is dependent on its position in the 
hierarchy of the network and combinatorial and additive relationships are crucial
45
. 
Another author suggested that “the final effect of ILs on insulin sensitivity is likely to 
depend on a subtle balance of their relative concentrations (high or low), kinetics (acute 




Cytokines directly inhibit the insulin signalling cascade 
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The process whereby insulin promotes glucose uptake is as follows; the insulin receptor 
floats in the muscle cell membrane, a 340,000D molecular weight tetramer encoded by a 
single gene. The two α-subunits sit outside the cell membrane and are attached to the two 
β-subunits by disulphide bonds.  The two β-subunits span the membrane and within the 
cell display tyrosine kinase activity. When insulin binds to the α-subunits the tyrosine 
kinase undergoes autophosphorylation which then allows interaction with other 
intracellular proteins, including insulin receptor substrate(IRS)-1 and IRS-2. The 
activated substrates recruit additional kinases and phosphatases in a complex signalling 
pathway that includes phosphatidylinositol-3-kinase (PI3K). PI3K activates the 
serine/threonine kinase Akt (Protein Kinase B) which induces the translocation of 
vesicles containing the glucose transporter GLUT4 to the cell membrane. The GLUT4 
receptors rapidly appear on the cell membrane within minutes of insulin stimulation and 
come from supplies of newly formed as well as recirculated receptors stored in vesicles. 
Signalling is switched off at multiple levels including dissociation of insulin and 
internalisation of the receptor; the action of intracellular protein tyrosine phosphatases 
such as PTP1b which deactivates the tyrosine kinase on the insulin receptor; the blocking 
of further activation of IRS-1 and other sites downstream; and Akt itself which can inhibit 
upstream insulin signalling. The mechanism of insulin resistance may act at several of 
these levels also. 
Cytokines, including TNF-α, IL-6 and IL-1 bind to membrane-bound receptors activating 
several intracellular protein kinases, notably c-Jun amino-terminal kinase (JNK) and 
inhibitor of nuclear factor κB kinase (IKK)
3, 6, 45
. Both lead to serine phosphorylation of 
IRS-1, which then prevents IRS-1 undergoing tyrosine phosphorylation on the insulin 
receptor and activating the insulin-signalling pathway. JNK and IKK interfere with 
signalling at other levels of the pathway and also influence gene expression leading to 
further cytokine production via effects on activator protein-1 and NFκB. Cytokines may 
induce other pathways that produce insulin resistance such as suppressor of cytokine 
signalling (SOCS) proteins and inducible nitric oxide synthase (iNOS). 
The chronic inflammatory process associated with obesity is also associated with 
increased lipid accumulation in muscle, liver and blood. While not the focus of this 
review, lipids may activate protein kinase C, which can lead to serine phosphorylation of 
IRS-1 as well as activate other kinases
47
. Lipid interaction with fatty-acid-binding 
proteins and nuclear receptors can also induce further inflammatory cytokine expression. 
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However even the role of lipids is complicated by lipid-ligands to transcription factors 




The trigger for inflammation 
The chronic inflammatory response seen with obesity appears to originate in, and is 
largely driven by, the increasing adipose tissue mass
6, 45
. The reason why an increase in 
adipose tissue should trigger such an inflammatory response is not clear. Theories have 
suggested factors such as hypoxia, oxidative stress and endoplasmic reticulum (ER) 
stress, although there is clearly some overlap between these. 
 It is proposed that obesity leads to hypoxia of adipose tissue due to a combination of 
increasing adipose cell size, reduced capillary density and limited diffusion distance of 
oxygen
48
. The cellular response to hypoxia includes activation of hypoxia inducible 
factor(HIF)1-α leading to the coordinated expression of a number of adaptive genes, 
including inflammatory mediators. In support of this, the adipose tissue of obese mice 
was found to have reduced blood flow and lower oxygen tension than that in lean mice, 
and over-expression of a number of stress responsive genes
49
.  Further, polarographic 
Clark electrodes inserted into obese human adipose tissue found lower oxygen levels and 
increased insulin resistance as measured by hyperinsulinaemic euglycaemic clamp
50
. 
However the change in adipose tissue oxygen did not correlate with the glucose dispersal 
rate. Obstructive sleep apnoea is characterised by repeated episodes of hypoxia and has 
been associated with increased levels of TNF-α, CRP and IL-6 independent of obesity
51, 
52
. Treatment with nasal CPAP reduced the levels of these inflammatory mediators. In 
another study, non-obese male volunteers were found to develop insulin resistance 
measured by clamp after 2 days of exposure to the relative hypoxia of high altitude 
however this was largely compensated by 7 days
53
. Non-obese male volunteers were also 
found to develop insulin resistance by clamp studies after a 30-minute exposure to 
hypoxia sufficient to lower SpO2 from 96% to 75%
54
. While significant hypoxia appears 
to induce insulin resistance, it is unclear whether the lower oxygen level recorded in 
obese adipose tissue is actually a metabolic stress. Hypoxic stress may be indicated by an 
increase in lactate effusion from the adipose tissue suggestive of increased glycolysis and 
decreased oxidation of glucose for metabolism. A recent study using tissue-specific 
10 
 
venous catheterisation found that obese adipose tissue did have reduced oxygen delivery 
but has low oxygen demand and showed no metabolic evidence of hypoxia
55
.  
Oxidative stress may be precipitated by the increased nutrient supply to adipose tissue. 
The increasing amount of glucose transported across the endothelial cell membranes 
places a large metabolic strain on the mitochondria which results in increased production 
of reactive oxygen species (ROS)
6
. The rise in intracellular ROS activates inflammatory 
signalling cascades which lead to macrophage attraction and infiltration, exacerbating the 
inflammatory response. 
The endoplasmic reticulum (ER) is an organelle that serves multiple functions in the cell. 
Proteins are synthesized on the cytoplasmic surface of the ER, and those destined for 
secretion or for transmembrane compartments are translocated into the ER, where they 
undergo posttranslational modifications such as disulphide bond formation or 
glycosylation, and are correctly folded and assembled to their final three dimensional 
conformation. Factors that interfere with ER function, such as lipids, increased synthesis 
of secretory proteins, infection or hypoxia lead to accumulation of unfolded or misfolded 
proteins. ER stress triggers the unfolded protein response (UPR) with the goal of rescuing 
the cell. The UPR is typically regulated by three transmembrane proteins, PERK (PKR-
like ER-resident kinase), ATF6 (activating transcription factor 6) and IRE1 (inositol-
requiring enzyme 1). The activation of these enzymes leads to a range of changes in cell 
function but includes increased ROS generation, activation of JNK and IKK pathways 




So far, the discussion linking a chronic inflammatory state with insulin resistance has 
been in association with obesity. It is pertinent to note that not all people with diabetes, or 
with insulin resistance, are obese. One study has looked at the relationship between 
inflammatory markers and insulin sensitivity in a large population cohort (1,221 males 
aged about 70 years)
57
. Insulin sensitivity was measured by hyperinsulinaemic 
euglycaemic clamp. The whole cohort did demonstrate that higher serum levels of CRP 
and IL-6 were associated with reduced insulin sensitivity. Amongst a cohort of men with 
normal BMI and no diabetes or metabolic syndrome (n=382) the relationship of raised 
CRP and IL-6 with reduced insulin sensitivity was still maintained. This indicates that a 
11 
 
state of chronic inflammation is independently associated with insulin sensitivity; it does 
not necessarily have to be in association with obesity.   
Hyperbaric oxygen treatment 
Hyperbaric oxygen treatment (HBOT) is the breathing of 100% oxygen while exposed to 
increased atmospheric pressure.  It involves placing a person in a steel chamber which is 
pressurised usually to between 2 to 3 atmospheres absolute (ATA), with a hood or mask 
system providing 100% inspired oxygen. Treatments last 90-120 minutes and are 
typically provided as a course of 20-40 sessions. HBO has been a recognised therapy in 
the management of decompression illness and air embolism.  Increasingly, clinical studies 
are demonstrating a benefit for a variety of medical conditions including non-healing 
wounds (particularly in people with diabetes)
58
, tissue damage as a result of 
radiotherapy
59
 and necrotising tissue infections
60
. The hyperoxia will provide vital 
oxygen to tissue with marginal perfusion however there is increasing interest in HBOT’s 
ability to influence cell signal transduction cascades
61
. The supraphysiological levels of 
oxygen achieved with HBOT have been shown to stimulate secretion of growth factors, 
VGEF and heat shock proteins, mobilise stem cells and modulate specific activity of 
neutrophils.   
A proportion of patients referred for HBOT have diabetes and it has been an observation 
that people with diabetes tend to experience a fall in their blood sugar level (BSL) during 
HBOT exposure. Six patients with diabetes had their BSL followed by laboratory 
glucometer over the course of a 2-hour HBOT
62
. BSL fell by a mean 3.5 mmol/l with no 
change in serum insulin. Another study compared 237 glucometer BSLs pre and post-
HBOT in patients with diabetes, finding a mean fall of 2.04mmol/l
63
. The change in BSL 
was greater in those taking insulin compared to oral hypoglycaemics, and there was no 
change in HbA1c. Another study followed 41 patients with diabetes and found a mean 
fall in BSL of 23%
64
. The mechanism of this effect has not been examined and it is not 
apparent whether this is specific to those with diabetes or whether those without diabetes 
are able to compensate for it. Since a chronic inflammatory state is strongly associated 
with reduced insulin sensitivity, it is appropriate to consider what is known about the 
effect of HBOT on immune function.  
Most studies of HBOT demonstrate suppression of inflammation although a few suggest 
an enhanced response. One study using healthy subjects and a brief compression to 2 and 
12 
 
2.8ATA breathing air or oxygen found a doubling of TNF-α while at pressure but which 
was not evident 30-minutes later
65
. There was evidence of lipid peroxidation but no 
change in serum IL-6 and IL-1β. Two other studies using an in vitro macrophage 
preparation found that prior HBOT exposure induced an exaggerated release of TNF-α 
when the macrophages were stimulated by lipopolysaccharide (LPS) exposure
66, 67
. 
HBOT has demonstrated immunomodulation in many studies using several different 
models of inflammatory injury. In a mouse study using caecal ligation and puncture as a 
model for septic peritonitis, 12-hourly HBOT was associated with improved survival 
possibly by mechanisms involving increased IL-10
68
. Survival was maximal at a pressure 
of 2.5ATA with no survival advantage at lower pressures and increased mortality at 
higher pressures, suggesting that the protection is dose dependent. In a mouse model bred 
for the development of atherosclerosis, daily HBOT at 2.4ATA for 5 weeks reduced the 
degree of histological change in the wall of the aorta, while also reducing inflammatory 
markers and increasing antioxidant pathways
69
. Spleen cells from the HBOT group 
showed increased levels of IL-10 while LPS activation led to reduced expression of TNF-
α, IL-6 and IL-1β. A further rat study used zymosan injected into the peritoneum to 
induce a model of multiple organ dysfunction
70
. Two sessions of HBOT at 2ATA reduced 
the degree of visible peritonitis as well as reduced plasma levels of TNF-α and IL-1β. 
There was reduced expression of TLR-2 and TLR-4, a pathway known to activate NFκB. 
An in vitro human monocyte model exposed to HBOT at 2.4ATA and stimulated with 
LPS revealed reduced expression of TNF-α and IL-1β
71
. Interestingly, this effect was 
only found for HBOT at 2.4ATA, there was no change in monocytes exposed to 
normobaric oxygen or to pressure alone. Also, the degree of suppression in the HBOT 
group was related to the duration of exposure. Suppression was maximal after 30-
minutes, continued exposure for 3-hours returned the response to baseline while exposure 
for 12-hours produced even greater release of inflammatory markers. While these studies 
used different animal species and different models, they point to the importance of the 
oxygen “dose” determined by the pressure and duration of HBOT exposure. Normobaric 
oxygen exposure (ie 100% oxygen at 1ATA) does not induce immunomodulation while 
exposure to oxygen levels that are too high or for too long can worsen the outcome, 
presumably related to the onset of oxygen toxicity. Within this therapeutic window 
HBOT may suppress certain immune system responses to inflammatory stimuli. 
However, it is important to appreciate that very specific cell functions are affected 
13 
 
without a global effect on the immune system as a whole that could lead to 
immunocompromise. For example, HBOT has been shown to reversibly interfere with 
CD11/18 activity on the neutrophil membrane, an effect which has been utilised in the 
clinical management of ischaemia-reperfusion injury
72
. However the neutrophil will still 
respond normally to endotoxin and LPS exposure and phagocytosis and related activities 
are preserved.  
Reactive oxygen species 
Adipose tissue that is subjected to stress, either oxidative or by the ER increasing ROS 
production, activates other pro-inflammatory pathways and reduces insulin sensitivity. 
ROS have generally been thought of as the toxic waste product of oxidative cell 
metabolism and only likely to induce a negative change, such as reduced insulin 
sensitivity. It seems counterintuitive to then suggest that HBOT may be beneficial when 
HBOT undoubtedly generates a large amount of ROS and reactive nitrogen species 
(RNS)
61
. Important in reconciling this conflict is the realisation that ROS and RNS are 
also signalling molecules in the transduction cascades and pathways of cell activity. 
HBOT exposures are relatively brief while at the same time HBOT acutely enhances the 
antioxidant responses in tissue with effects on superoxide dismutase and catalase. There 
appears to be a subtle interplay between the oxygen dose and its tissue-specific effect on 
the opposing influences of increased ROS and enhanced anti-oxidant activity. A degree of 
oxidative stress seems crucial to the action of HBOT however oxygen toxicity could 
negate the benefit. 
The concept that some oxidative stress may be beneficial is reflected in the experimental 
use of HBOT as a preconditioning agent. Preconditioning is the prophylactic use of a 
manoeuvre to better prepare tissue for a known, deliberate challenge. It is most 
commonly employed in the setting of cardiac bypass surgery or organ transplantation 
where tissues will suffer a period of ischaemia. Preconditioning manoeuvres have 
included a brief period of surgically-induced ischaemia and use of chemical agents such 
as carbon monoxide. HBOT used prior to cardiac surgery has resulted in improved 




A recent article has further complicated the ROS story by suggesting that ROS have the 
capacity to both promote and attenuate the insulin response
75
. There is clear evidence for 
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the association of obesity and T2DM with oxidative stress, and for ROS being involved in 
insulin resistance. Essentially, mitochondrial dysfunction and ER stress can lead to 
intracellular ROS generation with subsequent activation of JNK and IKK pathways. What 
has now become apparent is that ROS are involved in normal insulin signalling. Insulin, 
while activating the tyrosine kinase within the insulin receptor, also co-ordinately 
inactivates the enzymes responsible for turning off the cascade that leads to GLUT4 
translocation. These enzymes include members of the protein tyrosine phosphatase family 
such as PTP1B (which dephosphorylates the insulin receptor tyrosine kinase activation 
loop) and PTEN (which interrupts PI3K signalling downstream). These enzymes are very 
susceptible to reversible oxidation. Insulin appears to stimulate the activity of NADPH 
oxidase within the cell membrane adjacent to the insulin receptor leading to generation of 
ROS which act locally to inhibit protein tyrosine phosphatase activity and augment the 
insulin signal. ROS appear to be vital in normal cell signalling as well as propagating 
pathological processes. Which of these aspects predominate may depend on where in the 
cell the ROS are generated and whether the response is acute or chronic. 
Postscript 
At this stage of research, we have one published paper
76
 while another is in preparation. 
In these studies, we have been able to show that 3 sessions of HBOT leads to a significant 
increase in insulin sensitivity in those with T2DM and further, that it occurs in those 
without diabetes also. These results suggest our line of investigation has valid scientific 
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Abstract
Aim Hyperbaric oxygen therapy is known to reduce fasting blood glucose in individuals with Type 2 diabetes. However,
the mechanisms of this effect are not clear. The aim of this study was to determine whether peripheral insulin sensitivity by
hyperinsulinaemic euglycaemic clamp is increased in patients presenting for hyperbaric oxygen therapy.
Methods Participants were non-obese individuals without Type 2 diabetes (n = 5) or obese patients with Type 2 diabetes
(n = 5). Patients were given 100% oxygen at 2.0 absolute atmospheres for 2 h, six sessions per week for 5 weeks.
Results Peripheral insulin sensitivity was increased in the whole cohort (P = 0.04). Subsequent analysis revealed that this
was significant at both treatment 3 (+37.3  12.7%, P = 0.02) and treatment 30 (+40.6  12.6%, P = 0.009). HbA1c was
significantly reduced in subjects without diabetes only (P < 0.05).
Conclusion Insulin sensitivity increased within 3 days of hyperbaric oxygen treatment and this was maintained for 30
sessions. This increase in insulin sensitivity is equivalent to that observed following moderate weight loss. The mechanisms
underlying the insulin-sensitizing effect of hyperbaric oxygen require further elucidation.
Diabet. Med. 29, 986–989 (2012)
Keywords adipose tissue hypoxia, hyperbaric oxygen, insulin resistance, obesity
Abbreviation HOMA-IR, homeostasis model assessment of insulin resistance
Introduction
Uses of hyperbaric oxygen therapy include decompression
sickness and to aid wound and ulcer healing in Type 2 diabetes
mellitus. There is some evidence that hyperbaric oxygen
reduces fasting blood glucose in patients with Type 2 diabetes
[1,2] by at least 20% [2–4] and lowers HbA1c and the
inflammatory marker, C-reactive protein and fasting insulin
resistance, as measured by homeostasis model assessment of
insulin resistance (HOMA-IR) [3]. However, no studies have
examined whether hyperbaric oxygen therapy changes periph-
eral insulin sensitivity as assessed by the gold standard, the
hyperinsulinaemic euglycaemic clamp. It is also not clear
whether the hyperbaric oxygen-induced reduction in blood
glucose is unique to people with diabetes, or a physiological
change for which individuals with Type 2 diabetes are unable
to compensate. The aim of this study therefore was to deter-
mine whether peripheral insulin sensitivity is improved during
hyperbaric oxygen treatment in humans, and whether this
occurs in individuals with and without Type 2 diabetes.
Subjects and methods
Patients
Non-obese individuals without Type 2 diabetes or obese males
with Types 2 diabetes, aged 40–80 years, presenting for an
initial assessment for hyperbaric oxygen therapy to the
Hyperbaric Medical Unit of the Royal Adelaide Hospital were
screened for participation. Indications for hyperbaric oxygen
treatment included diabetic ulcer (n = 2), mandibular osteo-
radionecrosis (n = 6) and radiation proctitis (n = 2). All indi-
viduals with diabetes were receiving insulin therapy and three
were also receiving oral hypoglycaemic agents; both were
withheld on the mornings of the clamp. No medications were
changed during the study. Participants were excluded if they
Correspondence to: Leonie K. Heilbronn, The University of Adela-
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were inpatients, had recent or current active systemic infection,
were using corticosteroids or had changes in insulin require-
ments within the last 3 months. The study was approved by the
Human Ethics Committee and participants provided written
consent.
Study design
Participants were studied in the Hyperbaric Unit on three
occasions at 08.00 h after fasting from midnight the preceding
night and were instructed not to change usual exercise habits
over the course of the study. To assist this, patients were also
provided with car parking facilities on site. Height and weight
was recorded and two cannulae were placed intravenously in
contralateral arm veins. Fasting blood samples were taken and
the hyperinsulinaemic clamp (80 mU m)2 min)1) was initiated
with a variable infusion of 25% dextrose to clamp blood glu-
cose levels at 6 mmol ⁄ l. The first 80 min of the clamp was
performed in ambient air according to previously described
techniques [5] and the last 2 h was performed either in ambient
air at baseline, or during the 3rd and 30th exposure to hyper-
baric oxygen treatment. Glucose infusion rate was calculated as
the final 30 min of the clamp and adjusted for body surface
area of the patient. Blood samples were assessed using a bedside
glucose monitor (Accucheck Advantage; Roche Diagnostics,
Castle Hill, NSW, Australia), using a glucose dehydrogenase
method that is accurate when the sample oxygen level is high.
The sample was also sent for later assessment in the laboratory.
One blood sample was taken for measurement of steady-state
insulin. The hyperbaric oxygen treatment schedule for study
participants was identical to treatment received by patients not
enrolled in the study. This involved daily treatment from
Monday to Saturday (6 days ⁄ week) for 30 treatments.
Each treatment lasted for 2 h and involved compression to
2 atmospheres absolute, breathing oxygen via a ‘hood’ sys-
tem for 90 min with a 30-min decompression back to
1 atmosphere.
Biochemistry
Serum insulin was measured by electrochemiluminescence
(Modular e170; Roche Diagnostics). C-peptide was measured
using two-site chemiluminescence (Immulite 2000; Siemens,
Bayswater, VIC, Australia). Glucose was measured using a
hexokinase method (Olympus 4500; Beckman, Brea, CA,
USA). HbA1c was measured by cation exchange chromatog-
raphy (Variant II; Bio-Rad Laboratories, Gladesville, NSW,
Australia).
Statistical analysis
Analyses were performed using SPSS version 15.0 (SPSS Inc.,
Chicago, IL, USA) with one-way ANOVA or repeated-mea-
sures ANOVA, and subsequent testing of time points was
performed using the paired t-test. P < 0.05 was considered
significant and data are presented as mean  se, unless stated
otherwise.
Results
Baseline patient characteristics are presented in Table 1. Indi-
viduals with Type 2 diabetes were heavier (P < 0.001). Fasting
glucose and insulin were not different between groups, as there
was high variation in Type 2 diabetes, but HbA1c was signifi-
cantly higher in individuals with Type 2 diabetes (P = 0.007).
Peripheral insulin sensitivity was not statistically lower in those
with Type 2 diabetes (P = 0.1).
Peripheral insulin sensitivity was significantly increased by
hyperbaric oxygen therapy at three and 30 visits in the whole
cohort (P = 0.04, Fig. 1a). Subsequent analysis revealed this
was significant at both treatment 3 (+37.3  12.7%, P = 0.02)
and treatment 30 (40.6  12.6%, P = 0.009). There was no
group effect, although splitting the data set revealed that sig-
nificance was reached only in those with Type 2 diabetes
(P = 0.008), with four out of five individuals without diabetes
improving insulin sensitivity (P = 0.1, Fig. 1b). HbA1c was also
significantly reduced in subjects without diabetes (P = 0.05,
Fig. 1c), indicating a reduction in average blood glucose levels
over the preceding weeks. However, fasting blood glucose
(Fig. 1d) and insulin (data not shown) were not changed at
treatment 3 or treatment 30 in either individuals with Type 2
diabetes or those without (P = 0.4 and P = 0.2, respectively).
Steady-state insulin was higher in subjects with Type 2 diabetes
(221  41 vs. 120  18 mU ⁄ ll, P < 0.05), as is often
described in the literature [5], but this was not altered by
hyperbaric oxygen treatment in either group (data not shown).
Discussion
This study is the first to show that insulin sensitivity is increased
during hyperbaric oxygen therapy. This improvement is rapid,
occurring within three treatments, and is sustained at least until
the 30th treatment. The increase in insulin sensitivity was
substantial, and similar in magnitude to the increase we have
previously reported following 12% body weight loss at 1 year






Age (years) 65  4 66  14 0.91
Weight (kg) 68.0  12.4 91.0  9.1 0.01
BMI (kg ⁄ m2) 21.3  2.9 31.3  3.3 0.001





Glucose (mmol ⁄ l) 5.8  1.0 9.9  6.9 0.24
Insulin (mU ⁄ l) 7.3  1.9 16.9  5.0 0.15
C-peptide (nmol) 856  226 725  312 0.74
Means  sd.
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in patients with Type 2 diabetes undergoing a diet and exercise
programme [6].
Current lifestyle trends are characterized by low levels of
physical activity and over consumption of energy-dense foods.
This has led to a worldwide increase in the prevalence of
obesity. as well as a number of metabolic disturbances,
including the development of insulin resistance. This is defined
as a relative impairment in the ability of insulin to exert its
effects on glucose and lipid metabolism in target tissues (e.g.
skeletal muscle, liver) and is considered one of the best
predictors of the future development of Type 2 diabetes [7].
Despite this, the causes of insulin resistance in humans remain
unclear. Recently, two studies have shown that fasting glucose
is reduced in patients with Type 2 diabetes following hyper-
baric oxygen therapy [3,4], with significant increases in
HOMA-IR also reported [4]. In this study, despite the small
sample size that was tested, we showed significant increases of
approximately 40% in peripheral insulin sensitivity following
hyperbaric oxygen treatment, providing a potential mechanism
for the reductions in fasting glucose observed in past studies.
This improvement was approximately twice that reported
previously by HOMA-IR [4]. Whilst the improvement in
peripheral insulin sensitivity only reached statistical significance
in patients with Type 2 diabetes, four out of five individuals
without diabetes also improved insulin sensitivity following
hyperbaric oxygen treatment and had reductions in HbA1c,
suggesting this insulin-sensitizing effect was not confined to
individuals with Type 2 diabetes only. This reduction in
HbA1c, in the absence of reduced fasting glucose, also supports
improved insulin sensitivity, as it suggests there was reduced
postprandial glucose. However, greater numbers of people
should be tested and future studies should test healthy indi-
viduals without any associated illnesses that may impact the
results. However, as the insulin-sensitizing effect was observed
within 3 days and hyperbaric oxygen does not promote wound
healing so rapidly, we do not believe it likely that changes in
health were the cause of the improvements in insulin sensitivity
observed.
The mechanisms underlying this improvement in peripheral
insulin sensitivity were not tested and may provide novel in-
sight into the pathogenesis of insulin resistance. During
hyperbaric oxygen treatment, oxygen is delivered at high
concentration under increased pressure, and the increase in
insulin sensitivity observed may be attributable to either factor
alone or a combination of both. Hyperbaric oxygen increases
the oxygen delivery to blood and tissues by more than 10-fold,
and thus we speculate that hyperbaric oxygen treatment may
act to improve insulin sensitivity by reducing adipose tissue
hypoxia and subsequently inflammation. It is increasingly
recognized that obesity and Type 2 diabetes are characterized
by adipose tissue dysfunction, including increased adipocyte
size and local tissue hypoxia [8]. Adipose tissue hypoxia has
been linked to endoplasmic reticulum stress and chronic low-
grade inflammation, both of which directly inhibit the insulin
signalling cascade [9,10]. Recently, C-reactive protein was
shown to be reduced following hyperbaric oxygen therapy [3],
indicating that chronic low-grade inflammation may be par-
tially resolved. Unfortunately, blood samples were not stored
for later assessment in this study and so we cannot test this
response and whether it was different between individuals with
and without Type 2 diabetes. There are also alternative
mechanisms of action, as hyperbaric oxygen treatment may act
(a) (b)
(c) (d)
FIGURE 1 Insulin sensitivity at baseline (visit 0) and during the third (visit 3) and 30th (visit 30) treatment with hyperbaric oxygen therapy (a) in the whole
cohort; or (b) grouped into individuals with and without Type 2 diabetes (Type 2 diabetes vs. no diabetes), (c) HbA1c and (d) fasting glucose by group at
baseline and during hyperbaric oxygen therapy. *P < 0.05 vs. baseline; P = 0.05 vs. no diabetes.
ª 2012 The Authors.
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to improve insulin sensitivity by stimulating mitochondrial
biogenesis. Increased expression of the master regulator of
mitochondrial biogenesis, peroxisome proliferator activated
receptor-1 alpha (PGC1a), has been shown following hyper-
baric oxygen therapy at 1.25 atmospheres absolute and 36%
oxygen in rats [11]. This may be important, as individuals with
Type 2 diabetes and those with a family history of Type 2
diabetes have reduced PGC1a expression and reduced mito-
chondrial function [12–15], which has been linked to increased
lipid accumulation and reduced insulin action in muscle [16].
However, this is also speculative and further research in this
area is required.
In summary, hyperbaric oxygen treatment is associated with
increased insulin sensitivity, with onset by 3 days and persis-
tence for at least 5 weeks. The insulin-sensitizing effect of
hyperbaric oxygen treatment is probably present in people
without as well as with Type 2 diabetes, at least in this patient
population. Unanswered questions remain, including the
duration and cause of the effect. Further studies may provide
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The findings from the pilot study encouraged further investigation, however more 
resources would be required. With the support of my supervisors and co-investigators, we 
found appropriate funding for the next step – a larger study that sought participants rather 
than patients and also made available a metabolic laboratory which allowed investigation 
of possible mechanisms of action for this insulin-sensitising effect of HBOT. 
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Hyperbaric oxygen therapy increases insulin sensitivity in overweight 
men with and without type 2 diabetes
David Wilkinson, Mirjam Nolting, Mohd Kaisan Mahadi, Ian Chapman and Leonie Heilbronn
Abstract
(Wilkinson D, Nolting M, Mahadi MK, Chapman I, Heilbronn L. Hyperbaric oxygen therapy increases insulin sensitivity 
in overweight men with and without type 2 diabetes. Diving and Hyperbaric Medicine. 2015 March;45(1):30-36.)
Aims: The onset of insulin resistance is an important metabolic event in the development of type 2 diabetes. For patients 
with type 2 diabetes, we recently showed that peripheral insulin sensitivity was increased during hyperbaric oxygen treatment 
(HBOT). This study aims to investigate whether this occurs in a non-patient population with and without type 2 diabetes, 
along with the mechanism of this effect.
Methods: Overweight and obese male participants were recruited from the community, 11 without and eight with type 
2 diabetes. Insulin sensitivity was measured by the glucose infusion rate (GIR) during a hyperinsulinaemic euglycaemic 
clamp (80 mU·m-2·min-1) at baseline and during the third HBOT session. Monocyte chemo-attractant protein-1 (MCP-1), 
tumour necrosis factor-χ (TNF-χ) and interleukin-6 (IL-6) were measured in fasting serum and adipose tissue samples taken 
for their gene expression at baseline and immediately following four HBOT sessions. Additional fasting serum samples 
were collected during the first HBOT at 0, 60 and 120 minutes, and 24-hours after the last HBOT.
Results: In response to HBOT, GIR was increased by 29 ± 32% in those without (n = 10, P = 0.01), and by 57 ± 66% in 
those with type 2 diabetes (n = 7, P = 0.04). This increase was maintained for 30 minutes post HBOT. Reduced MCP-1 
and TNF-χ were observed after HBOT, whereas IL-6 was increased only in individuals without diabetes and this correlated 
with the increase in insulin sensitivity (r2 = 0.72, P = 0.004).
Conclusions: Peripheral insulin sensitivity was increased following HBOT in overweight or obese males with and without 
type 2 diabetes; this increase was maintained for at least 30 minutes post HBOT. Changes in inflammatory cytokines may 
partly explain this effect.
Key words
Endocrinology, hyperbaric oxygen, obesity, diabetes, inflammation, metabolism, hyperbaric research
Introduction
Hyperbaric oxygen treatment (HBOT) is defined as breathing 
100% oxygen at a pressure greater than 101.3 kPa and is used 
clinically to treat a range of conditions including non-healing 
wounds.1  When patients with type 2 diabetes undergo 
HBOT they sometimes report symptoms of hypoglycaemia, 
while studies have shown that fasting glucose levels are 
reduced by a greater amount during HBOT as compared 
to room air in patients with type 2 diabetes.2,3  In a recent 
pilot study of hospital patients with type 2 diabetes who 
were receiving a prescribed course of HBOT for a medical 
condition, we showed that insulin sensitivity, as measured 
by the hyperinsulinaemic euglycaemic clamp technique, was 
increased during the third and the thirtieth HBOT sessions.4 
The mechanism was not investigated and it was unknown 
whether the insulin-sensitising effect was influenced by their 
medical conditions improving over time.
Insulin resistance is defined as a relative impairment in the 
ability of insulin to exert its effect on glucose metabolism in 
target tissues (e.g., skeletal muscle, liver) and is considered 
one of the best predictors of the future development of type 2 
diabetes.5  Obesity is also associated with insulin resistance,6 
and both obesity and type 2 diabetes are increasing in 
prevalence and have become major health issues globally. 
Obesity-related insulin resistance is closely associated 
with a chronic, low-grade inflammatory response within 
adipose tissue, characterised by immune cell infiltration, 
altered cytokine production and activation of inflammatory 
signalling pathways.7  Pro-inflammatory cytokines linked to 
insulin resistance include tumour necrosis factor (TNF)-χ,8 
monocyte chemo-attractant protein (MCP)-1,9,10 interleukin 
(IL)-611,12 and members of the IL-1 family; IL-1, IL-1 
receptor antagonist (IL-1ra) and IL-18.13–15
This study aims to determine whether the insulin-sensitising 
effect of HBOT can be demonstrated in a relatively healthy 
urban population including those with and without type 2 
diabetes, whether the effect is still measurable after exit 
from the hyperbaric chamber and whether HBOT-induced 
changes in insulin resistance are associated with changes 
in pro-inflammatory cytokines in serum and adipose tissue 
known to be associated with insulin resistance.
Methods
The study received ethics approval from the University of 
Adelaide and the Royal Adelaide Hospital (approval no: 
100615). All investigations were conducted in accordance 
with the Declaration of Helsinki and all subjects provided 
written informed consent.
SUBJECTS AND SCREENING 
Advertisements and a web-recruitment company were 
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used to enlist overweight and obese male volunteers
(BMI > 25kg·m-2) who had no other excluded medical 
conditions apart from the sub-group with type 2 diabetes. 
As insulin sensitivity can vary throughout the menstrual 
cycle, only male volunteers were recruited. We undertook no 
specific investigation of the diabetes status of the volunteers, 
the diagnosis of type 2 diabetes was made from their personal 
medical history together with the prescription of appropriate 
medication. Excluded medical conditions included 
anything that could potentially alter insulin response or the 
inflammatory pathways being investigated, such as: smoking; 
consumption of more than three standard alcoholic drinks 
per day; vigorous exercise more often than twice a week; 
conditions that might be associated with a pathological 
inflammatory process or could influence inflammatory 
markers (such as sleep apnoea, malignancy, autoimmune 
and inflammatory diseases) and medication that might affect 
angiogenesis, lipid metabolism or have anti-inflammatory 
properties. Each volunteer was assessed for suitability to 
enter the hyperbaric chamber by a hyperbaric physician 
according to the standard clinical criteria used at the facility; 
this included history, examination and audiology assessment. 
Body composition was measured by dual-emission X-ray 
absorptiometry (DXA) to calculate fat mass and fat-free 
mass (FFM). Nineteen male volunteers were recruited, aged 
45–70 years old, with BMI in the range of 24.3 to 45 kg·m-2.
STUDY VISITS 
Volunteers attended the Hyperbaric Medicine Unit at the 
Royal Adelaide Hospital on six occasions following a 10-
hour overnight fast (Figure 1). Testing was undertaken at 
approximately the same time each morning and sampling 
was undertaken at a similar time each visit. Baseline 
assessments (V0) were performed one week and the 
following week participants attended the facility for five 
consecutive days (V1 to V5). Visits V1 to V4 included a 
routine 2-hour HBOT exposure. This involved compression 
to 203 kPa while breathing 100% oxygen for 90-minutes, 
followed by a linear decompression over 30 minutes and 
was administered in a rectangular twin-lock multiplace 
hyperbaric chamber (Fink Engineering/Cowan Engineering, 
Australia, 1994).
The 3.5-hour hyperinsulinaemic euglycaemic clamp was 
performed at baseline (V0) and visit V3. The baseline 
clamp was performed in normobaric room air, outside the 
hyperbaric chamber, as previously described.16  Briefly, two 
intravenous cannulae were inserted into veins on opposite 
arms. One cannula was connected to an infusion of insulin 
(Actrapid®, Novo Nordisk, Baulkham Hills, Australia) at a 
fixed rate of 80 mU·m-2·min-1, together with a variable-rate 
infusion of 25% dextrose (Baxter Healthcare, Toongabbie, 
Australia). The other cannula allowed five to 10-minutely 
blood sampling to assess blood glucose levels by a hand-
held glucometer (Accu-Chek Performa, Roche Diagnostics, 
Australia). The target blood glucose level was 6 mmol·L-1. 
Insulin sensitivity was calculated from the glucose infusion 
rate (GIR) during two separate 30-minute steady-state (SS) 
periods at the end of the 3.5-hour clamp; SS1 corresponded 
with the period 2.5 to 3 hours and SS2 with 3 to 3.5 hours. 
The GIR was then standardized against FFM for each 
volunteer. The clamp was repeated during visit V3 with the 
two-hour HBOT session administered between the one- and 
the three-hour period of the clamp.
Therefore, when considering insulin sensitivity results, 
SS1 represented the last 30 minutes of the HBOT session 
while SS2 reflected the first 30 minutes immediately post-
HBOT. Serum insulin was measured during both steady state 
periods. To avoid any physical effort that might influence 
glucose uptake, the volunteers remained sedentary in a chair 
which was wheeled in and out of the hyperbaric chamber. 
One non-diabetic subject was unable to adequately perform 
middle ear equalization during the first HBOT and took no 
further part in the study. Data from SS2 were not available 
for two volunteers.
Blood samples were taken at three time points during the first 
HBOT at visit V1: at time zero (pre-HBOT) and at 60 and 
120-minutes relative to the 2-hour HBOT session. Further
blood samples were taken at visit V4 (immediately after the
fourth HBOT) and V5 (24 hours later). Blood samples were 
analysed for fasting glucose and insulin as well as cytokine
markers of inflammation that are known to be associated with 
insulin resistance (TNF-χ, IL-6, IL-18, IL-1ra and MCP-1).
Abdominal subcutaneous adipose tissue was biopsied  at
baseline (V0) and visit V4 according to previously described 
techniques, snap frozen in liquid nitrogen and subsequently
analysed for gene expression of inflammatory markers (IL-6, 
IL-1ra, TNF-χ and MCP-1).16
LABORATORY ANALYSIS 
Blood glucose samples sent to the laboratory were analysed 
by the hexokinase method (Olympus 4500, Beckman, USA) 
and insulin was measured by radioimmunoassay (Merck 
Figure 1
Timeline of study visits; V1–V5 were at same time of day on 
consecutive days; V0 was during the preceeding week
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Millipore, Billerica, MA, USA). Serum cytokine levels 
were determined using ELISA (R&D systems, Minneapolis, 
MN, USA). Total RNA was extracted from 100 mg adipose 
tissue using TRIzol reagent (Invitrogen, Carlsbad, CA). 
The integrity and concentration of RNA was assessed by 
spectrophotometry (Nanodrop, 2000, Thermoline). cDNA 
was synthesized using Omniscript RT kit (Qiagen, GmbH, 
Germany) and recombinant RNAsin ribonuclease inhibitor 
(Promega, Madison, WI) according to kit instructions. For 
RT-PCR analyses, we used gene-specific primer probes 
from Taqman (MCP-1, IL-6, TNF-χ, IL1-ra) and Taqman 
universal PCR master mix (Applied Biosystems, Darmstadt, 
Germany). The samples were run in duplicate on an ABI Fast 
7500 system (Applied Biosystems, Darmstadt, Germany) 
with internal negative controls and a standard curve. The 
cycle threshold (CT) value for each sample was normalized 
to the CT value of 18S ribosomal RNA to normalise for any 
changes in sample amplification, which was not different 
between V0 and V4.
STATISTICS
Statistical analysis was performed using SPSS for Windows 
(Version 19, SPSS Inc., Chicago, IL). Data were checked 
for normality by Shapiro-Wilk and log transformed prior 
to analysis if necessary. Differences between groups were 
analysed using one-way ANOVA. All other outcomes were 
analysed with linear mixed effects models using maximum 
likelihood estimation. Correlations were analysed by linear 
regression with coefficient of determination (r2) and P value 
(Statistica v6, Statsoft, Tulsa, OK). Baseline characteristics, 
GIR and serum insulin were reported as median with 95% 
confidence intervals (CI
95
). Significance was considered at 
P < 0.05.
Results
The baseline characteristics of groups stratif ied by 
diabetes status are shown in Table 1. Those with type 2 
diabetes had higher fasting glucose (P < 0.001) and lower 
insulin sensitivity by hyperinsulinaemic clamp (Figure 2,
Figure 2
(A) Glucose infusion rate at baseline (V0) vs. HBOT (V3)
during Steady State-1 (last 30 min of HBOT) in individuals
with and without type 2 diabetes; (B), Glucose infusion rate at
baseline vs. HBOT at Steady State-2 (first 30 min after HBOT)
(mean and SEM, * P < 0.05, † P < 0.01) 
Table 1
Baseline characteristics of men, stratified by diabetes status; median (95% CI), * P ≤ 0.001
Type 2 diabetes (n = 8) No diabetes (n = 11)
Age (years) 53 (49–60) 64 (53–66)
Height (m) 1.76 (1.69–1.79) 1.74 (1.69–1.80)
Weight (kg) 99.1 (87.9–111.5) 92.8 (80.4–108.5)
Body mass index (kg m-2) 30.8 (29.8–35.5) 30.5 (27.5–34.6)
Body fat (%) 35 (30–40) 32 (29–38)
Glucose (mmol·L-1) 9.8 (8.0–12.9) * 5.4 (5.0–5.9)
HDL (mmol·L-1) 1.2 (0.9–1.3) 1.2 (0.9–1.5)
LDL (mmol·L-1) 3.4 (2.1–4.2) 3.4 (2.1–4.2)
Triglycerides (mmol·L-1) 1.8 (0.8–4.9) 1.7 (1.0–2.0)
Total cholesterol (mmol·L-1) 5.6 (4.4–6.8) 5.3 (4.5–5.9)
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P = 0.006). A significant time effect was observed in the 
change in insulin sensitivity during the HBOT session 
(Figure 2A). For the group without diabetes, the median 
GIR at baseline in SS1 was 49.8 (39.6–62.7) µmol·kg·
FFM-1·min-1. This increased during HBOT to 61.7 (49.4–82.1) 
µmol·kg·FFM-1·min-1. For the group with type 2 diabetes, 
baseline median GIR at SS1 was 32.6 (20.1–41.6) µmol·kg·
FFM-1·min-1, increasing to 39.1 (36.6–48.5) µmol·kg·
FFM-1·min-1 during HBOT. The increase in insulin sensitivity 
was maintained for an additional 30 minutes after exit from 
the hyperbaric chamber whilst breathing normobaric air in 
those without diabetes (n = 9, P = 0.008, Figure 2B), but this 
was not significant in the group with diabetes (n = 6, Figure 
Figure 3
(A) Fasting glucose; (B) Insulin; (C); Monocyte chemotactic
protein 1 – MCP-1; (D) Tumour necrosis factor – TNFχ; (E)
Interleukin–6 – IL-6 concentrations  taken prior to and during
the first HBOT exposure at 60 and 120 minutes, immediately
following the 4th HBOT and 24 hours after the final HBOT
(mean and SEM, * P < 0.05, † P < 0.01)
Figure 4
Relationship between the change in insulin sensitivity measured 
at visit V3 and change in serum interleukin–6 (IL-6) at visit V4
in non-diabetics (r2 = 0.72, P = 0.004)
2B). During the baseline hyperinsulinaemic euglycaemic 
clamp, steady state serum insulin was 204.3 (182.8–229.4) 
µU.ml-1 during SS1 and 199.2 (184.1–229.0) µU.ml-1 
during SS2, with no significant difference during HBOT.
We observed significant time effects for the change in 
glucose, insulin, MCP-1, TNF-χ and IL-6 with HBOT (all
P < 0.02), with a time*group (diabetes/no diabetes) 
interaction observed in the change in fasting glucose only 
(P = 0.03). Further analysis by group revealed significant 
reductions in fasting glucose during the first and fourth 
HBOT sessions at 120 minutes only in those with type 2 
diabetes (Figure 3A). Serum insulin was reduced during the 
first HBOT session in both groups (Figure 3B). MCP-1 was 
significantly reduced after HBOT at visits V1 and V4 in those 
without diabetes (Figure 3C), but this did not reach statistical 
significance in those with type 2 diabetes (Figure 3C). TNF-χ 
was significantly reduced 24-hours after the final HBOT 
in both groups (Figure 3D). In contrast, serum IL-6 was 
elevated in those without diabetes during and after HBOT 
at visits V1 and V4 (Figure 3E). The increase in IL-6 from 
baseline to visit 4 in the group without diabetes correlated 
with the increase in insulin sensitivity during SS2 (n = 9, 
r2 = 0.72, P = 0.004, Figure 4). Neither group showed any 
significant changes for IL-1ra and IL-18 (data not shown). 
Adipose tissue was analysed for gene expression of IL-6, 
MCP-1, TNF-χ and IL-1ra; however, no significant changes 
were detected (data not shown).
Discussion
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In this study, we have demonstrated that peripheral insulin 
sensitivity is increased following HBOT in a relatively 
healthy urban population sample. Moreover, we have 
demonstrated that the increase in insulin sensitivity occurs in 
overweight and obese males without diabetes as well as those 
with type 2 diabetes. Importantly, the insulin sensitising 
effect was maintained after exit from the hyperbaric chamber 
for at least 30 minutes. We also observed small changes in 
inflammatory cytokines following HBOT that may have 
partly contributed to the observed increases in insulin 
sensitivity.
Diabetes is a common contributing or coincidental factor 
in patients referred for HBOT. Within hyperbaric medicine 
practice, it has been recognised for some time that patients 
with diabetes are prone to a fall in blood glucose during 
HBOT.2,3  We also observed a signif icant fall in the 
blood glucose levels during the first HBOT in those with
type 2 diabetes. Although greater decreases in fasting glucose 
inside versus outside the chamber have been reported,2 we 
did not test this in our study and the changes could also 
be due to the prolonged length of the fast. Fasting glucose 
is predominantly under the control of hepatic glucose 
production; however, this was not specifically assessed in 
the current study. We also observed a fall in serum insulin 
during the first HBOT session in both groups; although other 
studies have found no effect of HBOT on insulin levels.2,17 
Our previous study tested a patient population during clinical 
HBOT exposure,4 whilst the current study, which found a 
similar increase in insulin sensitivity, was in volunteers with 
no clinical indication for HBOT.
HBOT may induce an insulin-sensitizing effect by a number 
of possible mechanisms. Here, we studied circulating 
concentrations of pro-inflammatory cytokines since these 
have been observed in obesity and are closely associated with 
insulin resistance.7  TNF-χ is a pro-inflammatory cytokine 
which is overproduced from adipose tissue in human 
obesity,8,18 and infusion of TNF-χ induces insulin resistance 
in humans.19  The pro-inflammatory cytokine MCP-1 is 
also overproduced from adipose tissue in obesity20 and 
impairs the insulin signalling cascade in a murine adipose 
tissue model independent of the associated macrophage 
infiltration.9,10  Reductions in both TNF-χ and MCP-1 were 
observed following HBOT and may partly explain the 
insulin-sensitizing effect, although the reduction in these 
cytokines did not correlate with the increase in insulin 
sensitivity.
IL-6 is a pleiotropic cytokine displaying both pro- and 
anti-inflammatory actions. Increased IL-6 is associated 
with human obesity and insulin resistance.11,21  Conversely, 
exercise, a known insulin sensitiser, is associated with a 
transient release of IL-6 from muscle,22 and acute infusion of 
IL-6 in humans leads to an increase in insulin sensitivity as 
measured by clamp studies.12  IL-6 was not changed in those 
with type 2 diabetes, but was acutely increased by HBOT 
in those without diabetes. Interestingly, this was positively 
associated with increased insulin sensitivity. However, the 
changes in IL-6 are clinically small and may be a chance 
finding. We did not observe changes in IL-6 expression in 
adipose tissue, but no other tissues were investigated in 
this study.
The literature is mixed regarding the effect of HBOT on 
circulating cytokines, although most studies support an 
anti-inflammatory action of HBOT. Animal models suggest 
HBOT has, in part, an anti-inflammatory action in positive 
outcomes to abdominal sepsis,23 multi-organ dysfunction24 
and development of atherosclerosis.25  Human clinical 
data suggest HBOT-induced immunomodulation may be 
behind reduced restenosis following coronary angioplasty 
and stenting,26 better outcome following cardio-pulmonary 
bypass,27 and following ischaemia-reperfusion-related 
soft-tissue crush injury.28  Even HBOT in the treatment 
of decompression illness is recognised to include an anti-
inflammatory modulation of neutrophil activity as part of 
the therapeutic mechanism.29  However, isolated cytokine 
changes should be interpreted with caution since the final 
effect on insulin sensitivity may depend on “a subtle balance 
of their relative concentrations (high or low), kinetics (acute 
or chronic) and targets”.15
Alternatively, it has been proposed that insulin resistance 
may be induced by adipose tissue dysfunction secondary 
to hypoxia.30  The growth of adipocytes in obesity is not 
matched by the blood supply, which may result in reduced 
oxygen delivery and regions of relative hypoxia.30  Certainly, 
lower oxygen partial pressures have been measured in 
the adipose tissue of obese humans compared to lean 
controls.31  However, another study concluded that adipose 
tissue had low oxygen consumption and the measurement 
of lactate/pyruvate ratios in blood draining this tissue 
revealed no evidence of metabolic stress.32  The effects of 
hyperbaric oxygen on adipose tissue physiology have not 
been reported previously.  However, studies investigating 
the reverse, using a hypoxic breathing gas mixture, have 
produced conflicting results. In two human studies using 
hyperinsulinaemic euglycaemic clamps, insulin resistance 
increased during acute exposure to hypoxia,33 but decreased 
after a more chronic hypoxia protocol.34  The substantial rise 
in tissue oxygen tensions associated with HBOT will also 
be accompanied by a transient increase in reactive oxygen 
species (ROS). This warrants further investigation since 
ROS, whilst having the potential to cause cell damage, 
also act as vital messengers in cell signalling,35 including a 
positive effect on insulin signalling.36
This study employed the hyperinsulinaemic euglycaemic 
clamp which is considered to be the gold standard technique 
to assess peripheral insulin sensitivity.37  Performing the 
clamp in a hyperbaric chamber was novel and required 
consideration of some technical issues and physiological 
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responses. Our glucometer used glucose dehydrogenase as 
the strip reagent, found to be more accurate than glucose 
oxidase when exposed to increased ambient oxygen.38 
Microvascular alterations in blood flow can influence 
measurement of insulin sensitivity as a consequence of 
varying the glucose delivery to the tissues.39  Therefore, it 
is relevant to consider that vasoconstriction is an expected 
physiological response to hyperbaric oxygenation.40  While 
the effects of HBOT on the microvasculature have not been 
tested, the sustained increase in insulin sensitivity observed 
upon exit from the hyperbaric chamber suggests our results 
were not influenced by changes in tissue blood flow. 
Insulin resistance is a pivotal early change in obesity-related 
type 2 diabetes. The identification of pathways that influence 
insulin responsiveness may potentially lead to clinical 
therapies that prevent the development or progression of 
this disease. This study introduces a pathway that has not 
previously been exploited. The new findings, that HBOT can 
also increase insulin sensitivity in those without diabetes and 
also that the effect is sustained for a period after HBOT, have 
implications beyond diabetes involving obesity and glucose 
metabolism broadly. Further studies are now required to 
describe the precise mechanisms involved and to define the 
time course of the insulin sensitising effect – how much 
HBOT is required to initiate the effect and how long it 
persists after leaving the hyperbaric chamber. 
Conclusions
This study has demonstrated that hyperbaric oxygen leads to 
an increase in insulin sensitivity in an overweight and obese 
male population with and without type 2 diabetes mellitus. 
Furthermore, the increase in insulin sensitivity was still 
evident 30 minutes after exiting the hyperbaric chamber. 
We have also demonstrated a favourable modulation of 
inflammatory markers in response to HBOT that may partly 
explain this effect on insulin sensitivity. 
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The insulin sensitivity results from the last study were consistent with the findings of the 
pilot study. Furthermore, changes in serum inflammatory cytokines for some of the 
important players in the chronic low grade inflammation story (TNF-α and MCP-1) 
suggested we might be on the right path. 
The finding that the increase in insulin sensitivity could be demonstrated in those without 
diabetes convinced us to continue our line of investigation using participants without 
diabetes because it would be technically easier and avoid changing diabetic medication 
together with fasting in preparation for the glucose clamp technique.  
The next goal was to investigate the timing of this insulin-sensitising effect – its onset and 
its duration. Previous studies had performed the glucose clamp during the third HBOT, 
partly in case some accumulated exposure to HBOT was required and also to give the 
participants the opportunity to practice their ear clearing technique prior to the day of 
running the glucose clamp in the chamber. So the next study we planned was to perform 
the glucose clamp during the first HBOT intervention. The study design required our 
participants to undertake two hyperinsulinaemic euglycaemic glucose clamps on 
consecutive days – the day of the first HBOT intervention and the day immediately prior. 
Although the glucose clamp technique was easy to manage in participants without 
diabetes and we had no specific issues during the study, on reflection I would not plan to 
perform two 3½ hour hyperinsulinaemic euglycaemic glucose clamps on consecutive 
days again. So when it came to investigating the duration of the insulin-sensitising effect, 
we recognised the need for a technique of assessing insulin sensitivity that might be easier 
for everyone concerned but could still be repeated on several occasions in a relatively 
short space of time. For this purpose, we chose a frequently sampled intravenous glucose 
tolerance test (FSIGT) using minimal model analysis. For this study, we reverted back to 
measuring insulin sensitivity during the third HBOT intervention, as this had provided 
reliable results so far, and then planned to repeat the FSIGT 24 hours later in room air. 
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The two techniques produced conflicting results in regard to insulin sensitivity. The 
subsequent publication focused on the insulin sensitivity results and discussion of the two 
techniques used. Although blood samples and adipose tissue biopsies were taken, they 
were not reported here.  
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Abstract 
Introduction: Previous studies using a hyperinsulinaemic euglycaemic glucose clamp 
have demonstrated an increase in peripheral insulin sensitivity in men with and without 
Type-2 Diabetes Mellitus on the third and thirtieth Hyperbaric Oxygen Therapy (HBOT) 
session. In two studies using different techniques for assessment of insulin sensitivity, we 
investigated the onset and duration of this insulin-sensitising effect of HBOT. 
Methods: Men who were obese or overweight but without diabetes were recruited. One 
study performed a hyperinsulinaemic euglycaemic glucose clamp (80mU.m-2.min-1) at 
baseline and during the first HBOT exposure (n=9). Data were analysed by paired t-test.  
The other study assessed insulin sensitivity by a frequently sampled intravenous glucose 
tolerance test (FSIGT) at three time points: baseline, during the third HBOT and 24-hours 
post-HBOT (n=9). Results were analysed by repeated-measures ANOVA. 
Results: There was a significant 23% increase in insulin sensitivity by clamp measured 
during the first HBOT exposure. The FSIGT showed no significant changes in insulin 
sensitivity. 
Conclusions: The hyperinsulinaemic euglycaemic glucose clamp demonstrated a 
significant increase in peripheral insulin sensitivity during a single, 2-hour HBOT session 
in a group of men who were obese or overweight but without diabetes. As an alternate 
technique for assessing insulin sensitivity during HBOT, the FSIGT failed to show any 
changes during the third HBOT and 24-hours later, however modification of the study 
protocol should be considered. 
Introduction 
While Hyperbaric Oxygen Therapy (HBOT) is not used to treat diabetes mellitus per se, 
it has been observed that when people with diabetes undergo HBOT they may experience 
a decrease in blood glucose levels (BGL), potentially inducing clinical hypoglycaemia.1, 2 
One study showed a substantial average BGL decrease of 3.5mmol.l-1 during a 2-hour 
HBOT session, with no change in serum insulin concentrations, suggesting an increase in 
insulin sensitivity as an underlying mechanism.3  
Insulin resistance is defined as a relative impairment of the action of insulin on target 
tissues, particularly muscle and liver. The development of insulin resistance is the best 
predictor of those likely to develop type-2 diabetes mellitus (T2DM) in the future.4 The 
inverse of insulin resistance is termed insulin sensitivity. In addition, obesity is strongly 
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associated with the development of insulin resistance and T2DM via activation of a 
chronic inflammatory state.5 The insulin resistance has effects on peripheral tissue 
glucose uptake as well as hepatic glucose production although an important effect is 
found in the peripheral tissues, specifically muscle.6  
Of the many techniques available to assess insulin sensitivity, the hyperinsulinaemic 
euglycaemic glucose clamp is the gold standard.7, 8 In a preliminary study of men (with 
and without T2DM) who were receiving a course of 30 HBOT sessions for medical 
indications, the glucose clamp technique revealed  a substantial and significant increase in 
insulin sensitivity from baseline during their third (37% increase) and thirtieth (41% 
increase) HBOT sessions.9  On subgroup analysis, this increase was significant only in 
those with T2DM, however numbers were small. A subsequent study, again using the 
glucose clamp technique, enrolled men who were obese or overweight (BMI>25kg.m-2), 
with and without T2DM.10 This study demonstrated significant increases in insulin 
sensitivity of similar magnitude during the third daily HBOT session in those with T2DM 
(57% increase) and without (29% increase). The increased insulin sensitivity was still 
measurable 30-minutes after exit from the hyperbaric chamber.  
Unanswered questions include how quickly the insulin-sensitising effect of HBOT 
occurs, how long it persists and its underlying mechanisms. To investigate this, we 
planned to assess insulin sensitivity during the first HBOT using the hyperinsulinaemic 
euglycaemic glucose clamp. However, while the glucose clamp technique is accurate, it is 
labour intensive and made more complicated by being performed within a hyperbaric 
chamber under pressure.  We therefore designed a further study to assess an alternate, 
technically easier method of assessing insulin sensitivity in the chamber, which if 
sufficiently accurate could be more easily used for repeated studies on the same 
participant. Having previously shown that the insulin-sensitising effect could be 
demonstrated in men without T2DM, we designed these studies using men who were 
obese or overweight (BMI>25 kg.m-2) but without diabetes.  This paper reports two 
studies: the use of the hyperinsulinaemic euglycaemic glucose clamp to test the effect on 
insulin sensitivity during the first HBOT session and secondly, the use of a frequently 
sampled intravenous glucose tolerance test (FSIGT) to assess insulin sensitivity during 
HBOT and after 24-hours. 
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Methods 
Both studies were approved by the Human Research Ethics Committee of the Royal 
Adelaide Hospital (RAH121212a, RAH140321) and the University of Adelaide and 
entered on a trial registry site (NCT02009813, NCT02136615). Both studies were carried 
out in accordance with the Declaration of Helsinki. All participants provided written, 
informed consent. 
PARTICIPANT SELECTION 
Both studies enrolled participants via local advertisement and a web-based recruitment 
company. Only men were studied as insulin sensitivity can vary throughout the menstrual 
cycle. Other inclusion criteria included age over 18 years with no history of diabetes; 
participants were obese or overweight (body mass index >25 kg.m-2). Exclusion criteria 
included prescribed or non-prescribed medication that may affect glucose homeostasis 
(e.g. corticosteroids); smoking; alcohol intake >140 grams/week; regular, high-intensity 
exercise (> twice per week); blood donation or involvement in any other study within the 
last 3 months. All participants were assessed for fitness to undertake HBOT by a 
hyperbaric physician.  
HYPERINSULINAEMIC EUGLYCAEMIC GLUCOSE CLAMP STUDY DESIGN 
The hyperinsulinaemic euglycaemic glucose clamp was first described by DeFronzo in 
1979.11 Insulin is infused at a constant rate that is above fasting levels, to stimulate 
glucose disposal in peripheral tissues but suppress hepatic glucose output. A variable dose 
glucose infusion is guided by regular blood sampling to measure BGL and “clamp” the 
BGL at a pre-determined level (in this case, 6mmol.l-1). After running the infusions for a 
period of time, a steady-state can be reached where BGL and glucose infusion are stable. 
At this point, the glucose infusion rate (GIR) is equal to the glucose disposal rate. The 
GIR is a direct measure of whole body glucose disposal for a given level of 
hyperinsulinaemia.8 
Ten participants were enrolled. A dual-emission x-ray absorptiometry scan (DXA) was 
performed at baseline for all participants to determine fat free mass (FFM). All 
participants attended the Hyperbaric Medicine Unit after overnight fasting (10-hours). 
Two IV cannulae were inserted into contralateral arms, one for the insulin and glucose 
infusions and the other for blood sampling. A primed insulin (Actrapid, Novo Nordisk, 
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Baulkham Hills, Australia) solution (80mU.m-2.min-1) was infused for 3½ hours as 
previously described.10 Blood samples were taken at 5-10 minute intervals and BGL 
measured by glucometer (Accu-Chek Performa, Roche Diagnostics, Sydney, Australia). 
BGL was maintained at 6mmol.l-1 with a variable infusion of 25% Dextrose (Baxter 
Healthcare, Old Toongabbie, Australia). Insulin sensitivity was determined by the GIR 
during two separate but consecutive 30-minute steady state (SS) periods in the last hour 
of the infusion; SS1 corresponded with 2½-3 hours and SS2 with 3-3½ hours. The GIR 
was standardised for FFM from the DXA scan. 
The following day, all participants returned after overnight fasting and the 3½ hour 
glucose clamp was repeated using the same protocol, this time overlayed with a 2-hour 
HBOT session. The twin-lock, multiplace hyperbaric chamber (Fink Engineering/Cowan 
Engineering, Australia, 1994) was compressed to 203 kPa followed by breathing 100% 
oxygen by mask or hood during 90 minutes at 203 kPa and a 30-minute linear 
decompression to 101.3 kPa. Insulin sensitivity was determined by the GIR during the 
same two SS periods, so SS1 coincided with the last 30-minutes of the 2-hour HBOT 
session and SS2 with the first 30-minutes after exit from the chamber. Statistical analyses 
were performed using Statistica (version 12, Statsoft, Tulsa, OK, USA). Paired t-test was 
used to compare GIR. Significance was considered at p<0.05.  
FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE TOLERANCE TEST 
STUDY DESIGN 
An indirect measure of insulin sensitivity was developed by Bergman in 1979 using 
mathematical modelling of glucose and insulin data from an intravenous glucose 
tolerance test.12 Following the glucose bolus, frequent measurement of blood glucose and 
insulin are made. The complex relationship between glucose and insulin in the disposal of 
glucose from the blood is built into pharmacokinetic models that are fit to the data. 
Parameters that provide best fit are derived. This includes insulin sensitivity (SI), defined 
as fractional glucose disappearance per insulin concentration unit.8 Other parameters 
include: glucose effectiveness (SG), the ability of glucose to promote its own disposal; the 
acute insulin response to glucose (AIRG) or first-phase insulin response; the disposition 
index (DI), a product of insulin sensitivity and insulin secretion, which is a constant. The 
mathematics to calculate these parameters has been packaged into a commercially 
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available software program. The FSIGT has shown reasonable correlation with the 
glucose clamp (r=0.54).7 
Twelve participants were enrolled. On the first study day (Day 1) all participants attended 
the Hyperbaric Medicine Unit at the Royal Adelaide Hospital after an overnight (10-hour) 
fast. A baseline FSIGT was performed in room air with the participant resting in a chair 
outside of the hyperbaric chamber according to the following protocol. Two intravenous 
lines were inserted into contralateral forearms and blood taken for time zero. A glucose 
bolus was given into one of the cannulae at time zero over 1 minute. The weight-
dependant bolus used 25% Dextrose (Baxter Healthcare, Old Toongabbie, Australia) at 
300mg.kg-1 to a maximum dose of 120ml (30gm Dextrose). Blood sampling from the 
other IV line was performed at 2, 4, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 60, 70, 90, 
120, 150 and 180 minutes. 
Each participant then underwent 3 HBOT sessions on consecutive days (Days 2-4), with 
compression to 203kPa breathing oxygen for 90-minutes and a 30-minute decompression. 
During the third HBOT session on Day 4, another FSIGT was performed using the same 
protocol as on Day 1. Compression of the chamber to 203kPa takes 7 minutes and time 
zero for the bolus Dextrose injection aligned with the start of oxygen breathing during the 
90-min period at 203kPa. A further FSIGT was performed 24-hours later on Day 5, in air
outside the hyperbaric chamber. The 3 FSIGTs were performed at a similar time of the
day.
Blood samples taken at each of the time points were analysed for glucose and insulin. 
Insulin was measured by radioimmunoassay (Millipore, St. Charles, MO, USA). Glucose 
was measured using commercial enzymatic kits on a Beckman AU480 clinical analyser 
(Beckman Coulter, Brea, CA, USA). All samples for each subject were analysed within 
the same analytic run to minimise instrument variation. The glucose and insulin data were 
entered into the minimal model software (MINMOD Millennium, Pasadena, CA, USA) to 
derive insulin sensitivity and the other parameters. These measures were statistically 
analysed by repeated measures ANOVA using SPSS for Windows (Version 22, SPSS, 
Chicago, IL, USA). Significance was considered at p<0.05. 
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Results 
HYPERINSULINAEMIC EUGLYCAEMIC GLUCOSE CLAMP 
One participant sustained a minor middle ear barotrauma during compression at the start 
of the HBOT. He was removed from the hyperbaric chamber and excluded from the 
study. Characteristics of the nine remaining participants are shown in Table 1. The GIR 
data were normally distributed by Shapiro-Wilk and Kolmogorov-Smirnov tests. Figure 
1A shows the GIR during SS1 (the last 30 minutes of the HBOT session). There was a 
significant increase in insulin sensitivity from Day 1 to Day 2, as measured by the GIR 
(t=-2.89, df=8, p=0.02). Figure 1B shows the GIR during SS2 (the first 30 minutes after 
leaving the chamber), the rise was not statistically significant (t=-1.87, df=8, p=0.10).  
[Insert Table 1 and Figure 1 here] 
Mean ± SD 
Age 47 ± 5.7 
Height (cm) 176.4 ± 10.3 
Weight (kg) 97 ± 15.1 
BMI (kg.m-2) 31.1 ± 3 
DXA fat free proportion (%) 64.3 ± 0.1 
Baseline insulin sensitivity 
(mg.kgFFM-1.min-1) 
8.57 ± 3.02 
Figure 1: (A) Glucose infusion rate (GIR) at baseline vs HBOT during 
SS1 (last 30-minutes in chamber); (B) GIR at baseline vs HBOT during 
SS2 (first 30-minutes after HBOT). *p=0.02 
Table 1: Demographics of 
participants (glucose clamp 
study, n=9). BMI: Body Mass 
Index, DXA: dual-emission x-
ray absorptiometry scan. 
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Table 3: Insulin sensitivity and other parameters derived from minimal 
model analysis (mean ± SD). SI: Insulin Sensitivity, SG: Glucose 
effectiveness, AIRG: Acute Insulin Response to Glucose, DI: 
Disposition Index. 
FSIGT 
One participant sustained a minor middle ear barotrauma at the start of compression and 
was removed from the hyperbaric chamber, another withdrew for personal reasons. Upon 
laboratory analysis, one further participant had glucose and insulin levels on arrival for 
the FSIGT on the third HBOT and again 24-hours later which suggested a failure to 
follow the fasting protocol, and these data were excluded. Characteristics of the 
remaining nine participants are shown in Table 2. The results of the minimal model 
analysis of the FSIGT are shown in Table 3. Data sets for all parameters showed large 
variances and there were no significant changes in any of the measured parameters.  
[Insert Table 2 and Table 3 here] 
Discussion 
Using an in-chamber hyperinsulinaemic euglycaemic glucose clamp technique, we have 
previously shown that routine HBOT typically used for clinical indications is associated 
with significant increases from baseline in peripheral insulin sensitivity on the third day 
of daily HBOT sessions.9, 10 Utilising the same clamp technique, we have now found that 
the HBOT-induced increase in insulin sensitivity occurs during the very first HBOT 
session. This study also confirms the previous findings that the insulin-sensitising effect 
Mean ± SD 
Age 37.1 ± 13 
Weight (kg) 99.3 ± 15.2 
Height (cm) 172.6 ± 3.8 
BMI (kg.m-2) 33.2 ± 4.1 
Day 1 Day 4 Day 5 
SI (mU.l-1.min-1) 3.35 ± 1.27 3.82 ± 2.09 4.23 ± 3.38 
SG (min-1 x100) 1.55 ± 0.79 1.58 ± 0.92 1.48 ± 0.82 
AIRG  (mU.l-1.min-1) 720 ± 462 573 ± 275 706 ± 364 
DI 2304 ± 2004 1862 ± 1115 2165 ± 1089 
Table 2: Demographics of 
participants (FSIGT study, n=9). 
BMI: Body Mass Index. 
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of HBOT can be identified in men without diabetes and is not specific to those with 
diabetes. The findings that the effect can be identified during the first HBOT exposure 
and in men without diabetes should make future studies examining the effects of HBOT 
on insulin sensitivity and the effects underlying them easier to undertake. 
In our previous study using the clamp technique, HBOT significantly increased insulin 
sensitivity not only during the final 30-minutes of the 2-hours spent under HBOT 
conditions, but also during the first 30-minutes after exit from the hyperbaric chamber, 
when performed on the third HBOT exposure.10 The current study used the glucose clamp 
technique on the first HBOT and found significantly increased insulin sensitivity under 
hyperbaric conditions (during Steady State 1). In contrast, there was not a significant 
increase over baseline insulin sensitivity during the first 30-minutes after leaving the 
chamber (Steady State 2). There is a trend towards an increase in insulin sensitivity, 
however small sample size and large variance in the data make statistical significance 
more difficult to achieve. Another consideration as to why Steady State 2 did not achieve 
significance in the current study could be that one HBOT has less impact than three – 
there was a 23% increase in insulin sensitivity during the first HBOT compared to a 29% 
increase in men without diabetes during the third HBOT.10 There may be some 
accumulation of the HBOT-effect with repeated exposures, however its duration of effect 
is not known. It is clear however, that one 2-hour HBOT session is sufficient to see a 
change in insulin sensitivity. This finding is also consistent with clinical practice in 
hyperbaric medicine where anecdotally, people with diabetes have experienced a fall in 
their BGL during their first HBOT session. 
Our previous studies performed the clamp on the third HBOT session for two reasons: to 
improve the chances of identifying an effect if some accumulated exposure was important 
and also to give the participant the opportunity to practice middle ear equalisation 
manoeuvres that are required during pressurisation of the hyperbaric chamber, prior to 
undergoing the glucose clamp procedure. While potential difficulty with ear equalisation 
was assessed during their initial medical review, middle ear barotrauma continues to be 
the most frequent complication associated with clinical HBOT (approximately 2%).13 
Indeed, one of our participants in this study had been established on his second glucose 
clamp with infusions of glucose and insulin when he was wheeled into the chamber only 
to find he couldn’t satisfactorily equalise his ears at the start of the compression. This 
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required his removal from the hyperbaric chamber and from the study. Even with the 
small sample size in this study, a significant increase in insulin sensitivity was identified, 
consistent with the two previously published studies.  
Our attempts to replace the glucose clamp technique with the simpler-to-use FSIGT 
however, have not been successful. While the FSIGT requires frequent blood sampling 
over several hours, it avoids the necessity of passing samples through the medical lock for 
immediate glucometer analysis and the rapid decisions required to maintain blood glucose 
concentrations during a glucose clamp.  However, under the same HBOT conditions as in 
our three glucose clamp studies, all of which showed increased insulin sensitivity during 
the first or third HBOT session, we found no significant effect of HBOT on insulin 
sensitivity when assessed by the FSIGT during the third HBOT and at 24-hours later. 
There are a number of reasons the FSIGT may have failed to pick up such an effect. The 
sample size was small. The FSIGT is known to be less reliable in people with insulin 
resistance. Several modifications to this technique have been suggested, such as giving 
Tolbutamide or an insulin infusion early in the FSIGT, which has improved the 
correlation with glucose clamp studies.7 However, in pursuit of a simpler technique and 
with a group of men without diabetes, we did not modify the FSIGT. Perhaps more likely, 
we performed the FSIGT too soon after the participants started their HBOT session. 
While we have demonstrated an increase in insulin sensitivity during steady state periods 
2½ to 3½ hours into the clamp (at the end of an HBOT exposure), we have not 
specifically tested insulin sensitivity earlier in the HBOT session using a glucose clamp 
technique. If the insulin-sensitising effect of HBOT requires some duration of exposure to 
activate, then giving the glucose bolus of the FSIGT at the beginning of the HBOT 
session may not be the best time. The bulk of the glucose disposal would have taken place 
in the early part of the HBOT session and missed a later-onset effect identified in the 
clamp studies. Future studies using the FSIGT should perform the procedure towards the 
end of the HBOT session. On a cautionary note, such a study design may have the 
potential for the fasting participant with diabetes to develop hypoglycaemia during their 
HBOT session, prior to the FSIGT and they would need regular monitoring of their in-
chamber BGL. If hypoglycaemia occurred during the HBOT, intervention would be 
required and the FSIGT would not be able to proceed. The third FSIGT performed 24-
hours post HBOT also did not demonstrate an effect of HBOT on insulin sensitivity, but 
we cannot say whether this is because such an effect was not present (i.e. a stimulatory 
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effect of the previous day’s HBOT had worn off), or whether such an effect was present 
but could not be detected due to limitations with the FSIGT technique. 
The FSIGT was chosen because it was anticipated to be easier to perform and more easily 
tolerated by the participant than the glucose clamp. In the end, both techniques were 
found to be labour-intensive in a hyperbaric chamber. Importantly for undertaking 
assessment of insulin sensitivity in the novel environment of a hyperbaric chamber, every 
endeavour was made to perform these techniques according to established protocols. The 
fasting participants were tested at the same time of the day. They were kept sedentary in 
comfortable chairs for the duration of the study and wheeled into and out of the 
hyperbaric chamber. The glucometer utilised a glucose dehydrogenase reagent as opposed 
to glucose oxidase, making it less sensitive to ambient oxygen pressures.14 
Our hyperbaric facility, along with many others, manages potential hypoglycaemia in 
patients with diabetes by monitoring their BGL before they enter the hyperbaric chamber 
and by repeating it if clinically indicated. Continued investigation is warranted in this 
field, both for the safety of hyperbaric patients with diabetes but also for the potential to 
identify novel pathways of glucose control. 
Conclusion 
The glucose clamp performed during the first HBOT session demonstrated a significant 
increase in insulin sensitivity, earlier than in our previously published studies which 
showed an increase in insulin sensitivity in men with and without diabetes on the third 
and thirtieth HBOT.9, 10 The hyperinsulinaemic euglycaemic glucose clamp appears to be 
a useful tool to undertake these investigations. The FSIGT in its current design is 
probably not a good tool to assess insulin sensitivity in a hyperbaric chamber. 
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The last publication described two different techniques for measuring insulin sensitivity 
and reported the results using these techniques during an HBOT intervention. Both 
studies also took blood samples and adipose tissue biopsies pre and post-HBOT for 
further investigation of possible mechanisms of action for an insulin-sensitising effect of 
HBOT based on the changes in inflammatory cytokines identified earlier. These blood 
and adipose tissue results were not included in the last publication, but have been 
analysed in a separate report written in manuscript style. They are unpublished. 
The literature review focused on an anti-inflammatory role for HBOT and the evidence 
for HBOT influencing inflammatory cytokine release and subsequent inflammatory 
processes involving ischaemia and sepsis, but is several years old now. Reviewing the 
cytokine data from these two studies revealed considerable inconsistency in the cytokine 
responses to HBOT. This provided the incentive to revisit the evidence, update the 
literature review in this respect and consider more recent evidence for HBOT having an 
impact on inflammatory cytokine release. 
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5c. Manuscript: 
Inflammatory cytokine production and adipose tissue gene expression in response to 
Hyperbaric Oxygen – unpublished data 
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Introduction: Obesity is associated with the release of inflammatory cytokines from 
adipose tissue creating a chronic low grade inflammatory state which is associated with 
insulin resistance. Hyperbaric oxygen therapy (HBOT) is widely considered to have anti-
inflammatory actions. We report two studies which measured changes in serum 
inflammatory cytokines and adipose tissue gene expression in response to HBOT. 
Methods: Men aged 18 years or older who were overweight or obese were recruited to 
either a study using a hyperinsulinaemic euglycaemic glucose clamp (n = 9) or a 
frequently sampled intravenous glucose tolerance test (FSIGT, n = 9). They underwent 
two or three HBOT interventions involving compression to 203 kPa (2 atmospheres 
absolute) for 90 minutes breathing oxygen via a hood, followed by a 30-minute 
decompression. The different study designs meant that blood sampling was not 
synchronised.  The clamp technique study sampled blood at baseline, at both the start and 
end of the second HBOT and 24 hours later and were analysed for inflammatory 
cytokines (IL-6, gp130, TNF-α, MCP-1, CRP and HSP-70). The FSIGT study sampled 
blood at baseline, at the end of the first and second HBOT and 24 hours after the third 
HBOT and were analysed for IL-6, gp130 and CRP. Abdominal adipose tissue biopsies 
were taken for gene expression analysis prior to HBOT and immediately after two HBOT 
interventions. Changes in serum cytokines and gene expression data were analysed by 
Wilcoxon Matched Pair Test. Given the time differences in sampling between studies, 
results are reported separately.  
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Results: Compared to baseline, the glucose clamp study demonstrated a within group 
increase in IL-6 at the start (P = 0.021) and the end (P = 0.008) of the second HBOT. 
Serum gp130 was decreased at the end of the second HBOT (P = 0.02). The FSIGT study 
demonstrated no change in IL-6 but a within group decrease in soluble gp130 at the end 
of the second HBOT (P = 0.038) as well as 24 hours after the third HBOT (P = 0.044). 
Gene expression from the clamp technique study revealed a decrease in MMP9 after two 
HBOT (P = 0.038). 
Conclusions: Serum IL-6 was increased and the related glycoprotein, soluble gp130, was 
decreased after HBOT in men who were overweight or obese. The increase in IL-6 found 
in the glucose clamp study was associated with a significant increase in insulin 
sensitivity. Further research should investigate the origin of the increased IL-6 and its 
association with an insulin-sensitising effect of HBOT.  
 
Introduction  
Metabolic research has identified that increased adipose tissue associated with obesity is a 
trigger for macrophage infiltration and activation.
1
 The subsequent systemic release of 
inflammatory cytokines, including tumour necrosis factor α (TNF-α), monocyte chemo-
attractant protein 1 (MCP-1) and interleukin 6 (IL-6) creates a chronic low grade 
inflammatory state that has been associated with the development of insulin resistance, 




In a series of publications, we have demonstrated an insulin-sensitising effect of 
hyperbaric oxygen therapy (HBOT) using the hyperinsulinaemic euglycaemic glucose 
clamp. First, we demonstrated a significant increase in insulin sensitivity in a group of 
patients with and without diabetes during their third and thirtieth HBOT.
3
 Subsequently, 
we demonstrated a significant increase in insulin sensitivity in a group of men who were 
overweight or obese, with and without diabetes during their third HBOT.
4
 This study also 
found a favourable decrease in serum inflammatory cytokines in response to HBOT, 




Two further studies have been published, however they reported only the primary study 
outcome of the measurement of insulin sensitivity under hyperbaric conditions.
5
 One 
study used an hyperinsulinaemic euglycaemic glucose clamp technique while the other 
study used a frequently sampled intravenous glucose tolerance test (FSIGT). Both studies 
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also had blood samples and adipose tissue biopsies taken, which are now being reported 
here. While the participant characteristics of these two studies were generally similar, the 
timing of the blood samples – determined by the insulin sensitivity test scheduling – 
varied between studies. The results must therefore be considered separately. 
 
The aim of this study was to investigate any change in serum inflammatory cytokines or 
in the expression of genes involved in adipose tissue inflammation and remodelling for a 
group of men who were overweight or obese following HBOT; and further, if any 
changes were associated with an insulin-sensitising effect of HBOT. 
 
Methods 
Both studies were approved by the Human Research Ethics Committee of the Royal 
Adelaide Hospital (RAH121212a, RAH140321) and the University of Adelaide and 
entered on a trial registry site (NCT02009813, NCT02136615). Both studies were carried 




The participants were the same as those reported in the publication investigating 
techniques to measure insulin sensitivity under hyperbaric conditions.
5
 Briefly, they were 
men who were overweight or obese (body mass index >25 kg.m
-2
), aged over 18 years 
with no history of diabetes or other significant medical conditions. The clamp technique 
study recruited ten participants; one participant who suffered a minor ear barotrauma on 
his first HBOT was excluded from the study. The FSIGT study recruited twelve 
participants; one suffered a minor ear barotrauma during HBOT, one withdrew for 
personal reasons and another was excluded when laboratory data revealed a failure to 
follow fasting instructions. Both studies report the results from nine participants.  
 
STUDY DESIGN 
Participants underwent an overnight fast prior to each study day. The primary outcome 
for both studies – measurement of insulin sensitivity – was undertaken during the first 
HBOT intervention in the clamp technique study and during the third HBOT in the 
FSIGT study and have been previously reported.
5
  Blood sampling for inflammatory 
cytokines was not possible on the days of insulin sensitivity measurement and so the 
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timing of the samples was not synchronised for both studies.  The clamp technique study 
had bloods taken for baseline several days prior to HBOT intervention, then at the start of 
the second HBOT (i.e. 24 hours after the first HBOT) and the end of the second HBOT 
and then 24 hours later. Blood was analysed for inflammatory related cytokines TNF-α, 
MCP-1, IL-6, C reactive protein (CRP), glycoprotein 130 (gp130) and heat shock protein 
70 (HSP-70). Baseline bloods were taken immediately prior to HBOT in the FSIGT study 
and then immediately after the first and the second HBOT interventions. The 24 hour 
blood sample in the FSIGT study was taken after having had three HBOT interventions. 
Blood was analysed for IL-6, gp130 and CRP. Abdominal subcutaneous adipose tissue 
was biopsied at baseline and after two HBOT interventions for both studies, according to 
previously described techniques,
6
 snap frozen in liquid nitrogen and subsequently 
analysed for gene expression related to a range of genes involved with macrophage 
activity (CD40, CD68, CD163), angiogenesis (VEGFα, ANGPT2) and extracellular 
matrix remodelling (COL3A1, COL6A1, MMP2, MMP9, TIMP1).  
 
LABORATORY ANALYSIS 
Serum cytokines were measured using commercial ELISA kits (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s instructions. Total RNA was 
extracted from ~ 100 mg sample of adipose tissue using TRI Reagent (Sigma, St. Louis, 
USA) following the manufacturer’s instructions as described previously.
7
 The 
concentration and purity of RNA were assessed by NanoDrop Lite Spectrophotometer 
(Thermo Fisher Scientific, CA,USA). cDNA synthesis was conducted using T100 
Thermal Cycler (Bio-Rad, CA, USA) with 1000 ng of each RNA sample using the 
QuantiTect reverse transcription kit (Qiagen, Valencia, CA,USA) according to kit 
instructions. Quantitative real-time PCR was performed using the Taqman primers (Table 
1) for macrophage (CD40, CD68, CD163), angiogenesis (VEGFα, ANGPT2) and 
extracellular matrix (COL3A1, COL6A1, MMP2, MMP9, TIMP1) and Fast Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The samples were run in 
duplicate on an ABI 7500 sequence detection system (Applied Biosystems, Foster City, 
CA, USA) with internal negative controls and a standard curve (pooled from each 
participant). Relative gene expression was analysed using the 2
−∆CT
 method and  
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Statistical analyses were performed using Statistica (version 12, Statsoft, Tulsa, OK, 
USA). Pre-post changes in serum cytokines and gene expression were analysed by 
Wilcoxon Matched Pairs Test for each study separately. Significance was considered at P 
< 0.05.  
 
Results 
In the glucose clamp study we found a significant increase in serum IL-6 in response to 
HBOT (Figure 1A). Compared to baseline, IL-6 was increased at the start of the second 
HBOT (24 hours after the first HBOT, P = 0.021) as well as at the end of the second 
HBOT where mean levels more than doubled (Table 2, P = 0.008). However, IL6 levels 
had returned to basal levels 24 hours after the second treatment. There was no change in 
IL6 after 1 or 2 HBOT interventions, or 24 hours after the third HBOT in the FSIGT 
study (Figure 1B, Table 3). 
 
Gene symbol Gene name Assay ID 
Housekeeping   
ACTB Actin beta Hs01060665_g1 
Macrophage   
CD68 CD68 molecule Hs02836816_g1 
CD40 CD40 molecule Hs01002913_g1 
CD163 CD163 molecule Hs00174705_m1 
Angiogenesis   
VEGFα 
vascular endothelial 
growth factor α 
Hs00900055_m1 




COL3A1 Collagen type III alpha 1 Hs00943809_m1 
COL6A1 Collagen type VI alpha 1 Hs01095585_m1 
MMP2 Matrix metallopeptidase 2 Hs01548727_m1 







Figure 2: Serum soluble gp130 from 2A: the glucose clamp study showed gp130 
decreased from baseline compared to the end of the second HBOT. (* P = 0.02) 2B:  
The FSIGT study showed gp130 decreased from baseline compared to the end of the 




In the glucose clamp study, we also found a significant decrease in serum soluble gp130 
from baseline as compared to the end of the second HBOT (Figure 2A, P = 0.02), but 
gp130 was not different from basal levels compared to 24 hours after the first HBOT 
(Pre-HBOT #2) or 24 hours after the second HBOT. In the FSIGT study, there was also a 
reduction in soluble gp130 in response to HBOT (Figure 2B). Compared to baseline, 
soluble gp130 was reduced at the end of the second HBOT (P = 0.038) and at 24 hours 
after the third HBOT (P = 0.044).  
 
There was no change in serum concentration of other cytokines measured in the clamp 














Figure 1: Serum IL-6 concentrations from 1A: the glucose clamp study showed IL-6 
increased from baseline compared to 24 hours after one HBOT (Pre-HBOT #2) and 
immediately after the second HBOT. (* P = 0.021, † P = 0.008) 1B:  The FSIGT study 
showed no change in IL-6 after one or two HBOT, or 24 hours after the third HBOT.  
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Table 2: Serum inflammatory cytokines in the glucose clamp study, expressed as mean (SD). 
IL-6 was increased before and after the second HBOT. Gp130 was decreased after the second 
HBOT. (* P = 0.021, † P = 0.008, ‡ P = 0.02) 
Table 3: Serum inflammatory cytokines in the FSIGT study, expressed as mean (SD). 
Gp130 was decreased after the second HBOT and 24 hours after the third HBOT. (* P = 
0.038, † P = 0.044) 
Table 4: mRNA foldchange for genes analysed in both studies, expressed as mean 
(SD). There was a significant decrease in expression of MMP9 in the clamp 





















) 1.345  (0.836) 2.341  (1.492) * 3.198  (2.675) † 1.773  (0.919) 
Gp130 (ng.ml
-1
) 3.558  (0.492) 3.029  (0.724) 2.963  (0.481) ‡ 3.572  (1.064) 
CRP (mg.l
-1
) 2.24  (1.76) 2.69  (1.9) 2.59  (1.9) 3.84  (2.73) 
TNF-α (pg.ml
-1
) 1.832  (0.787) 1.520  (0.803) 1.831  (0.434) 1.718  (0.274) 
MCP-1 (pg.ml
-1
) 102.59  (31.33) 79.71  (48.3) 99.91  (39.18) 102.65  (45.18) 
HSP-70 (ng.ml
-1
) 0.048  (0.006) 0.057  (0.009) 0.055  (0.01) 0.05  (0.01) 





) 1.788 (0.889) 1.78 (0.942) 2.014 (1.138) 2.129 (1.041) 
Gp130 (ng.ml
-1
) 2.98 (0.48) 2.651 (0.228) 2.6 (0.323) * 2.702 (0.358) † 
CRP (mg.l
-1
) 3.29 (1.97) 3.44 (2.18) 3.62 (2.79) 3.88 (2.79) 
mRNA 
foldchange 
Clamp study (n=8) FSIGT study (n=9) 
Pre-HBOT Post-HBOT Pre-HBOT Post-HBOT 
CD68 1.62  (0.58) 1.24  (0.4) 1.01  (0.93) 0.53  (0.28) 
CD40 2.1  (2.0) 2.0  (1.43) 0.61  (0.44) 0.75  (0.65) 
CD163 1.19  (0.48) 1.11  (0.36) 1.01  (0.45) 1.06  (0.41) 
VEGFα 1.87  (0.93) 1.97  (1.23) 0.91  (0.51) 1.06  (0.87) 
ANGPT2 0.004 (0.006) 0.005 (0.008) - - 
COL3A1 1.13  (0.32) 1.42  (0.96) 0.94  (0.31) 0.96  (0.39) 
COL6A1 1.33  (0.32) 1.3  (0.31) 0.82  (0.18) 0.78  (0.17) 
MMP2 1.82  (0.41) 1.44  (0.38) 0.72  (0.27) 0.73  (0.27) 
MMP9 1.71  (1.65) 0.61  (0.56) * 2.07  (2.73) 0.52  (0.38) 
TIMP1 4.02  (3.14) 2.46  (1.21) 0.57  (0.6) 0.61  (0.74) 
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Analysis of gene expression data from adipose tissue samples in the glucose clamp study 
revealed a significant decrease in expression of MMP9 after 2 HBOT interventions (Table 





The two studies have shown that men who were overweight or obese have reduced serum 
soluble gp130 levels following two HBOT interventions. One of the studies – the glucose 
clamp study – found serum IL-6 was increased after HBOT. This study also reported a 
significant increase in insulin sensitivity following HBOT in this same group of men 
when measured using a hyperinsulinaemic euglycaemic glucose clamp.
5
 These results 
should be considered in the context of an earlier study where we also found an acute 
increase in serum IL-6 and a significant increase in insulin sensitivity after HBOT 




IL-6 is produced by many cell types although about one third of basal IL-6 secretion 
comes from macrophages within adipose tissue.
8
 It has traditionally been considered a 
pro-inflammatory cytokine and there is considerable evidence to support this. Women 
with obesity were found to have increased IL-6 levels and reduced insulin sensitivity as 
measured by the fasting insulin resistance index.
9
 Weight loss led to a reduction in IL-6 
and an improvement in insulin sensitivity. Another study found that people with obesity 
had increased IL-6 levels in serum and adipose tissue, but it was serum IL-6 that was 
found to be best associated with reduced insulin sensitivity as measured by the 
intravenous glucose tolerance test.
10
 Furthermore, IL-6 is one of the cytokines implicated 
in the chronic low grade inflammatory state associated with obesity and the subsequent 
development of metabolic disease.
2
 However, other evidence indicates a far more 
complex role for IL-6 where it has also been shown to have an anti-inflammatory role. 
Acute intravenous infusion of IL-6 in a group of men without diabetes resulted in 
improved glucose disposal during a hyperinsulinaemic euglycaemic glucose clamp.
11
 IL-6 
is also released by skeletal muscle. During physical exercise, more IL-6 is released from 
muscle and it becomes the predominant source of serum IL-6 with serum concentrations 
increasing by up to 100 times.
12
 At the same time, exercise itself has been shown to be an 
insulin sensitiser.
13
 That IL-6 can elicit such widely variable responses – from pro-
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inflammatory to anti-inflammatory – indicates considerable nuance in its action. A 
number of factors have been recognised to influence the IL-6 response including: whether 
the raised IL-6 is chronic or acute and its actual concentration, the source of the IL-6 and 
its target tissue as well as other classes of cytokines and co-factors that can modulate IL-6 
activity in a hierarchical fashion.
14, 15
 When IL-6 reaches target tissue, it can signal via 
two pathways, termed “trans” or classical signalling.
15-17
 Activation of the “trans” 
signalling pathway enables IL-6 to interact with a very broad range of tissues, eliciting a 
generalised inflammatory response which is implicated in the chronic low grade 
inflammatory state. The classical signalling pathway restricts serum IL-6 to bind to only a 
few tissue types (hepatocytes and some white cells) with a specific and modulated 
response. Glycoprotein gp130 is a major factor in determining which pathway IL-6 
activates. Gp130 is a ubiquitously expressed transmembrane receptor for the IL-6 family 
of cytokines. A small amount of gp130 detaches from membranes and exists as soluble 
gp130 in serum.
15
 Here it appears to buffer serum IL-6 levels along with the action of 
other co-factors.
16
  For example, a serum IL-6 complex that has already been primed to 
activate the “trans” signalling pathway by binding to a soluble IL-6 receptor, will bind 
preferentially with soluble gp130 in the serum and in doing so only permit activation of 
the classical pathway. Reducing the level of “trans” signalled IL-6 will reduce the pro-




The two current studies have demonstrated a significant and acute reduction in serum 
soluble gp130 in response to HBOT, but only one study also demonstrated a significant 
increase in serum IL-6. This increase in IL-6 in the glucose clamp study was also 
associated with an increase in insulin sensitivity in response to HBOT using a 
hyperinsulinaemic euglycaemic glucose clamp.
5
  In an earlier study of men who were 
overweight or obese but without diabetes, we also found a significant increase in serum 
IL-6 following HBOT as well as an increase in insulin sensitivity using the clamp 
technique.
4
 This earlier study also took adipose tissue biopsies for gene expression 
analysis where we found no significant change in IL-6 gene expression, suggesting that 
the increased serum IL-6 was not coming from adipose tissue. While we have not been 
able to determine the tissue origin of the increased serum IL-6 levels in these studies, the 
above evidence that muscle IL-6 increases insulin sensitivity
12, 13
 whereas adipose tissue 
IL-6  does the opposite,
10
 suggests that IL-6 may be coming from muscle in response to 
the HBOT and contributing to the HBOT-induced increased insulin sensitivity. Further 
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research into HBOT is recommended, including the use of techniques such as muscle 
biopsy to identify the source of IL-6 following HBOT. The role of soluble gp130 and the 
consequences of a decrease in serum levels following HBOT are not clear. However, the 
above discussion has indicated an important role for soluble gp130 to reduce the pro-
inflammatory, “trans” signalling of IL-6. In fact, current research is exploring the 





Our two studies found no change to cytokines other than gp130 and IL-6. Following 
HBOT given to men who were overweight or obese, there was no change to serum levels 
of TNF-α, MCP-1, HSP-70 or CRP. This was unexpected after our previous study where 
using a similar group of participants we found significant reductions in serum TNF-α and 
MCP-1 following HBOT.
4
 While the small numbers within these studies was a limitation, 
the inconsistency of the cytokine response was disappointing and was not suggestive of a 
robust response. A review of the literature was undertaken for other studies that measured 
a cytokine response to HBOT. The discussion about IL-6 signalling has alluded to how 
intricately entwined the events surrounding cytokine action can be and I have excluded in 
vitro studies because of the isolated nature of their investigation. Neither have I 
considered animal studies but I have included results for some hormone responses as well 
as cytokines. The results are shown in Table 5. There is considerable variability in the 
reported results. Earlier studies encouragingly dismissed concern that the HBOT 
intervention may evoke a significant stress response reporting no change to cortisol and 
adrenaline.
18, 19




 or remain 
unchanged.
22
 No change is reported to serum IL-1β levels.
20-22
 Relevant to the current 
studies, IL-6 has previously been reported to rise in response to HBOT in three 
publications
4, 22, 23
 but others have found no change
20




Gene expression from adipose tissue biopsies showed little change after two HBOT 
interventions with only a decrease in MMP9 for the clamp technique study. MMP9 is a 
member of the matrix metalloproteinase family – enzymes that degrade basement 
membrane and extracellular matrix and are released under a variety of circumstances. In 
the acute response to injury they are important for tissue repair but their overexpression is 
also linked to activation of inflammatory pathways and pathological processes such as 
metastasis and cerebrovascular disease.
24
 An earlier study performed adipose tissue  
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One HBOT to 2.0 or 2.8 atm 
abs, duration unknown. Blood 
5 minutes after 





 1999 8 male divers 
One HBOT to 2.5 atm abs for 
60 minutes. Blood 20 minutes 
after 
↑ Endothelin-1, ↓ cortisol 










One HBOT to 2.5 atm abs for 
60 minutes. Blood 24 hours 
later 
↑ HSP-70 
No change to vitamins A, 






One HBOT to 2 atm abs and 
then 2.8 atm abs for an 
unknown duration. Blood 30 
minutes after 
↑ TNF-α, Endothelin-1 






Three HBOT in 24 hours. 2.8 
atm abs for 80 minutes. Blood 
before and after each HBOT 









Daily HBOT for 3 days. 2.5 
atm abs for 90 minutes. Blood 
after first and third HBOT 
↓ insulin in control 
No change to growth 
hormone, insulin-like 




20 patients with 
diabetes and non-
healing wounds 
Daily HBOT for 14 days. 2.5 
atm abs for 75 minutes. Blood 
taken after 7 and 14 HBOT 
↑ IL-6 





11 men without 
diabetes 
8 men with 
diabetes 
Daily HBOT for 4 days. 2.0 
atm abs for 90 minutes. Blood 
after 1 and 4 HBOT and 24 
hours later 
↓ TNF-α in all men  
↓ MCP-1 and ↑ IL-6 in 
men without diabetes 




23 men with 
avascular necrosis 
of femoral head 
30 HBOT over 6 weeks, 30 
day break then 30 more 
HBOT. Blood after 15 and 30 
HBOT, and before and after 
second HBOT course 
↓TNF-α, IL-6 at each time 
point 






18 patients with 
diabetes and foot 
ulcers 
20 HBOT over 4 weeks. 1.5 
atm abs for 45 minutes. Bloods 
before and after course 
↑ IL-6, adiponectin 




Table 5 (previous page): Published human studies investigating the effect of HBOT on 
cytokines and hormones. 
 
biopsies on men who were overweight or obese, with and without diabetes, before and 
after four HBOT interventions.
4
 In this study, we reported no change to gene expression 
for IL-6, MCP-1, TNF-αand IL-1ra. I found no other studies that investigated gene 
expression in human adipose tissue after HBOT. A study investigating HBOT in people 
with non-healing wounds measured gene expression from wound biopsy tissue.
22
 They 
found an increase in MMP9 after 7 HBOT but a return to baseline after 14 HBOT. Other 
studies have measured the enzymatic activity of MMP9 in tissue. In rats using an 
ischaemic colonic anastomosis model, HBOT was associated with increased activity of 
MMP9 in the injured tissue and with improved outcome.
28
 In a mouse model of impaired 
wound healing, HBOT was associated with upregulation of MMP9 activity in wound 
tissue and with improved healing.
29
 Not surprisingly, MMP9 itself does not act in 
isolation. It interacts with other co-factors including the MMP9 inhibitor, TIMP1, which 
was unchanged in our studies. The small numbers are a limitation, however it is hard to 
make any conclusions from the gene expression data from our limited investigations. 
 
Another limitation is that we have only investigated men for this insulin-sensitising effect 
of HBOT because of physiological variability in insulin sensitivity during the menstrual 
cycle in women, however we would expect similar responses in women. 
 
In conclusion, while the literature displays considerable variability in the serum cytokine 
response to HBOT, we have found increased IL-6 and decreased soluble gp130 after 
HBOT in men who were overweight or obese. The glucose clamp study together with an 
earlier study
4
 both found that the increase in IL-6 following HBOT was associated with 
an increase in insulin sensitivity using the glucose clamp technique. Further research 
should investigate the origin and the role of the increased IL-6 and its relationship with 
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The prospect of testing the insulin-sensitising effect of HBOT against hyperbaric air was 
envisaged early in the series of studies. However, basic questions related to onset and 
duration of this effect took precedence. The incremental experience gained in these 
interval studies better prepared us to return to the HBOT vs hyperbaric air question as a 
final study within this formal thesis. Study design could be kept simple as we had shown 
that the insulin-sensitising effect of HBOT was demonstrable during the first intervention. 
Although we had demonstrated the effect in men without diabetes, we wanted to make 
this study directly relevant to the issue of diabetes and so we recruited men with type 2 
diabetes.  
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We have previously shown that hyperbaric oxygen therapy (HBOT) increased insulin 
sensitivity in men who were obese or overweight, both with and without type 2 diabetes. 
The aim of this study was to test whether this insulin-sensitising effect is seen in 
hyperbaric air (HA). 
Methods 
Men with type 2 diabetes who were obese or overweight were randomised to 2 groups – 
HBOT (n = 13) or HA (n = 11). A hyperinsulinaemic euglycaemic glucose clamp (80 
mU.m-2.min-1) was performed at baseline and during hyperbaric intervention. Both groups 
were compressed to 203 kPa (2 atmospheres absolute) for 90 minutes followed by a linear 
30-minute decompression. The HBOT group breathed oxygen via a hood while the HA
group breathed chamber air. Insulin sensitivity was assessed by the glucose infusion rate
(GIR) during the last 30 minutes in the hyperbaric chamber (SS1) and the first 30 minutes
after exit (SS2). Data were analysed for within-group effect by paired student t-test and
between-group effect by one-way ANOVA.
Results
HBOT increased GIR by a mean 26% at SS1 (P = 0.04) and by 23% at SS2 (P = 0.018).
There was no significant change in GIR during HA. A between-group effect was evident
for the change in GIR at SS1 in HBOT vs HA (P = 0.036).
Conclusions
The pathway by which insulin sensitivity is increased in men with type 2 diabetes
requires the high oxygen partial pressures of HBOT and should be further investigated.
Insulin sensitivity was not changed in hyperbaric air.
Introduction 
Hyperbaric Oxygen Therapy (HBOT) is defined as breathing near 100% oxygen while in 
a hyperbaric chamber pressurised to more than 101 kPa or 1 atmosphere absolute (atm 
abs).1 HBOT administered by clinical facilities typically uses pressure between 203-284 
kPa (2-2.8 atm abs), with a duration of treatment 90-120 minutes. HBOT is an evidence-
based treatment for conditions including decompression illness, cerebral arterial gas 




Although HBOT is not used to treat diabetes mellitus per se, the increasing prevalence of 
this disease means that diabetes, particularly type 2 diabetes, is a frequent co-morbidity in 
patients treated with HBOT. For some years, it has been apparent that people with 
diabetes who undergo HBOT may experience a decrease in their plasma glucose (PGL) 
during their treatment. Trytko et al used a hand-held glucometer to measure PGL before 
and after HBOT sessions in 27 patients with a mixture of type 1 and type 2 diabetes.2 
Over the 237 HBOT sessions they found a mean fall in PGL of 2.04 mmol.L-1. Ekanayake 
et al measured laboratory glucose in a group of 5 patients with type 2 diabetes over the 2-
hour duration of their HBOT session and found a mean fall of 3.5 mmol.L-1 at the end of 
HBOT.3 They found no change in serum insulin levels. 
 
 We investigated the effect of HBOT on insulin resistance and its reciprocal term, insulin 
sensitivity. Insulin resistance is defined as a relative impairment in the ability of insulin to 
exert its effect on glucose in target tissues (particularly muscle and liver). The 
development of insulin resistance is the best predictor for those likely to develop type 2 
diabetes in the future.4 Of the many investigative techniques used to assess insulin 
sensitivity, the hyperinsulinaemic euglycaemic glucose clamp is considered the gold 
standard.5, 6 In recent studies we have described an acute effect of HBOT to increase 
insulin sensitivity, as measured with the glucose clamp technique. A pilot study initially 
revealed that insulin sensitivity was increased in a cohort of men with and without 
diabetes receiving a clinical course of HBOT.7 Progressively we have demonstrated that 
insulin sensitivity was increased during the third HBOT session in a cohort of men with 
and without diabetes,8 and recently that the increase can be measured during the first 
HBOT session.9 
 
The aim of this study was to determine whether the insulin-sensitising effect seen during 
HBOT (while breathing oxygen at a very high partial pressure) is also present during an 
equivalent pressure excursion but using air as the breathing gas rather than oxygen.  
 
Methods 
The study was approved by the Human Research Ethics Committee of the Royal Adelaide 
Hospital (R20160801) and the University of Adelaide and entered on a trial registry site 
(NCT03138746, clinicaltrials.gov). The study was carried out in accordance with the 
Declaration of Helsinki. All participants provided written, informed consent. The study 
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was performed in the Hyperbaric Medicine Unit at the Royal Adelaide Hospital. 
Participant recruitment commenced in August 2018 and was closed due to reasons 
external to the study in December 2019.  
  
PARTICIPANTS 
Twenty-five participants were enrolled via a web-based recruitment company. Inclusion 
criteria were men aged 40 years or older who were obese or overweight (Body Mass 
Index (BMI) > 25 kg.m-2) with type 2 diabetes. Exclusion criteria included the presence 
of significant other medical issues, other non-prescribed medication that could affect 
glucose homeostasis, smoking, individuals who regularly perform high intensity exercise 
(> twice per week) and current intake of  > 140 g alcohol per week. All participants were 
assessed for fitness to enter the hyperbaric chamber by a hyperbaric physician (D.W.). 
Participants were randomised into two groups, HBOT and hyperbaric air (HA), stratified 
for BMI (BMI < 33 or BMI ≥ 33) by computer-generated, randomised block design in 
groups of 4. 
 
STUDY DESIGN 
Participants attended the Hyperbaric Medicine Unit on two occasions after overnight 
fasting (10 hours) and modification of their diabetic medication. On the first visit, 
participants sat in comfortable reclining chairs, breathing room air while the baseline 
glucose clamp was performed over 3½ hours. Intravenous cannulae were inserted, one in 
each forearm with one for the insulin and glucose infusions and the other for blood 
sampling. A primed insulin (Actrapid, Novo Nordisk, Baulkham Hills, Australia) solution 
(80 mU.m-2.min-1) was infused with blood samples taken at 5-10 minute intervals and 
PGL measured by a hand-held glucometer (Accu-Chek Performa, Roche Diagnostics, 
Sydney, Australia). PGL was clamped at 5.5 mmol.L-1 with a variable infusion of 25% 
Dextrose (Baxter Healthcare, Old Toongabbie, Australia). Insulin sensitivity can be 
assessed at a pre-determined point in the glucose clamp during a steady state (SS) period 
when glucose infusion rate (GIR) and PGL readings are stable. We assessed insulin 
sensitivity by the GIR during two separate but consecutive 30-minute SS periods in the 
last hour of the infusion; SS1 corresponded with 2½-3 hours and SS2 with 3-3½ hours. 




Two days later, participants returned after overnight fasting for a second glucose clamp 
using the same protocol, this time overlaid with a 2-hour session in the hyperbaric 
chamber. The insulin infusion was established one hour prior to entering the chamber. 
The large, triple-lock, multiplace hyperbaric chamber (Fink Engineering Pty Ltd, Warana, 
Australia) was compressed using air to 203 kPa (2 atm abs) and held at this pressure for 
90 minutes followed by a 30-minute linear decompression back to ambient pressure. In 
the hyperbaric chamber, oxygen was delivered to the HBOT group via a hood system the 
same as used in clinical HBOT treatments (Amron International Inc, Vista, CA) which 
was connected on reaching 203 kPa pressure and continued for the 2-hour session (apart 
from a routine 5-minute “air-break” taken half-way through by temporarily detaching the 
hood). The HA group, who underwent the same pressure profile, breathed chamber air 
throughout the hyperbaric session. The participants remained in their reclining chairs 
once the clamp procedure had commenced and were wheeled into and out of the 
hyperbaric chamber. Blood samples were sent out of the chamber via the medical lock for 
PGL estimation.  Insulin sensitivity was determined by the GIR during the same two SS 
periods, so SS1 coincided with the last 30 minutes of the 2-hour hyperbaric session and 
SS2 with the first 30 minutes after exit from the chamber. At each visit, blood was taken 
for serum insulin concentration before commencing the clamp infusions for fasting levels 
and during SS1 and SS2 to demonstrate hyperinsulinemia. Steady state insulin 
concentrations were not different between groups or between SS1 and SS2.  
 
STATISTICAL CONSIDERATIONS 
Statistical analyses were performed using Statistica (version 12, Statsoft, Tulsa, OK). 
Power analysis of earlier data suggested sample size of 20 in each group for power of 
80% and α of 0.05. GIR data were normally distributed by Shapiro-Wilk and 
Kolmogorov-Smirnov tests.  HBOT and HA groups were analysed by paired student t-test 
for within-group effects and ANOVA for between-group effect. Significance was 
considered at P < 0.05.  
 
Results 
Of the 25 men enrolled, one participant experienced technical issues during his 
hyperbaric session and loss of data required exclusion. The other 24 participants 




Table 1: Participant characteristics for 
HBOT (n=13) and hyperbaric air (n=11) 
groups. (BMI, body mass index; BSA, 
body surface area) 
Table 2: Diabetes medication 
used by participants. 
Table 3: Glucose infusion rates (mg.m-2.min-1) for HBOT and HA 
groups at baseline and during the hyperbaric intervention. 
 
 
There were no significant differences between the two groups. <Insert Table 1> The 
participants were prescribed between one and four medications in the management of 
their diabetes (median two), summarised in Table 2. <Insert Table 2> 
 
The GIR data for both the HBOT and HA groups at baseline and during the hyperbaric 
exposure, for SS1 and SS2 can be seen in Table 3. <Insert Table 3> Within the HBOT 
group, there was a mean 26% increase in GIR (median 17%) when compared to baseline, 
during SS1 (P = 0.04). There was a mean 23% increase in GIR (median 19%) during SS2 
(P = 0.018). The HA group revealed no significant changes in GIR at SS1 or SS2.  
 
One-way ANOVA for the change in GIR revealed a difference between groups at SS1 for 
HBOT vs HA (Figure 1, P = 0.036). A trend towards a between-group difference was 






 HBOT mean (SD) 
HA 
mean (SD) 
Age 62.3 (8.7) 56.3 (7.1) 
Weight (kg) 108.2 (21.5) 102.4 (13.1) 
Height (cm) 176.4 (6.7) 179.8 (10.3) 
BMI (kg.m-2) 34.7 (6.8) 31.8 (4.7) 
BSA (m2) 2.23 (0.21) 2.21 (0.17) 
Medication Number (n = 24) 
Metformin 21 
Insulin 5 
SGLT-2 inhibitors 8 
DPP-4 inhibitors 7 
GLP-1 receptor agonists 4 
Sulphonylureas 2 
 HBOT Hyperbaric air 






 mean (SD) 
Steady State 1 151 (71) 177 (86) 180 (73) 166 (83) 
Steady State 2 173 (87) 198 (85) 189 (91) 189 (81) 
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Figure 1: Change in Glucose 
Infusion Rate (mg.m-2.min-1), 
expressed as mean change and SD, 
for HA and HBOT groups at steady 




This study has demonstrated that one session of HBOT significantly increased peripheral 
insulin sensitivity in men with type 2 diabetes, but exposure to an equivalent pressure 
profile without breathing supplemental oxygen (the hyperbaric air group) had no effect. 
The effect of HBOT persisted for at least the first 30 minutes after exit from the 
hyperbaric chamber. 
 
The insulin-sensitising effect of HBOT observed in this study is consistent with that 
observed in our earlier studies. In a group of patients referred for clinical HBOT (5 men 
who were not obese and without diabetes and 5 men who were obese with type 2 
diabetes), the glucose clamp revealed a significant increase in insulin sensitivity in the 
whole group during the third HBOT (37% increase) and the thirtieth HBOT (41% 
increase) although subgroup analysis revealed the change was statistically significant only 
in the group with diabetes.7 A subsequent study recruited a cohort of men who were obese 
or overweight, both with (n = 8) and without (n = 11) type 2 diabetes.8 A 
hyperinsulinemic euglycemic glucose clamp performed during the third HBOT 
demonstrated an increase in insulin sensitivity of 57% in those with type 2 diabetes and 
29% in those without. We also found that the increase was still apparent during the first 
30 minutes after exit from the hyperbaric chamber. A further study performed the glucose 
clamp technique during the first HBOT session on men who were obese or overweight 
but without diabetes (n = 9).9 This demonstrated a significant 23% increase in insulin 
sensitivity during the first HBOT session. Encouragingly, the magnitude of the insulin-
sensitising effect in the current study is comparable with the effect sizes previously 
published and is large enough to be clinically significant. The effect has an onset of action 
within one HBOT session but its duration is not known. However, this study again found 
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that the insulin-sensitising effect of HBOT was still active for at least the first 30 minutes 
after exit from the hyperbaric chamber. 
 
The mechanism of action for the insulin sensitising effect of HBOT is also unknown. 
However, an important new contribution from this study is the finding that the hyperbaric 
air group showed no change in insulin sensitivity. We can say for the first time that the 
hyperbaric environment itself – where the increase in absolute pressure is transmitted 
throughout the human body and generates a number of recognised physiological 
responses – has no independent effect on insulin sensitivity, in men with diabetes at least; 
it also requires the very high oxygen partial pressures that are only delivered during 
clinical HBOT to increase insulin sensitivity. There have been no reports or studies that 
we are aware of to suggest that breathing high concentrations of oxygen in the absence of 
hyperbaric conditions affects insulin sensitivity, and it seems likely that both high oxygen 
concentrations and high pressures are needed to produce this effect.  
 
Previous findings that this effect can be detected in men with and without diabetes 
suggest that HBOT initiates a common metabolic response which is not confined to 
people with diabetes mellitus.8 If the underlying mechanism for this insulin-sensitising 
effect can be identified, it may offer a new therapeutic target. In earlier work we found 
the insulin-sensitising effect of HBOT was associated with some reductions in serum 
inflammatory cytokines,8 however this may only be part of the story. A number of the 
therapeutic benefits of clinical HBOT have now been shown to require the deliberate 
generation of oxidative stress as a consequence of breathing hyperbaric oxygen.10 
Reactive oxygen species can be damaging to biological tissue, however they have other 
vital roles where they act as signalling molecules in a number of cellular pathways for a 
range of growth factors, cytokines and hormones.11 Independently, other research has 
pointed out that reactive oxygen species can have both an inhibitory as well as a 
stimulatory effect on the intracellular glucose transport pathway.12 
 
The finding that there was no change to insulin sensitivity in hyperbaric air is an 
important outcome in its own right. While this study was not specifically designed to 
answer SCUBA diving questions, it is interesting to consider that the hyperbaric air group 
undertook a simulated (dry) SCUBA dive, albeit perhaps not a typical dive profile. Their 
intervention was the equivalent of diving, on air, to 10 metres seawater for a 90-minute 
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bottom time followed by a very slow ascent to the surface over 30 minutes (so results for 
any “deeper” intervention cannot be assumed). This is relevant because people with 
diabetes do present to dive physicians with a desire to undertake SCUBA diving as 
recreation, with medical approval. For the dive physician, the medical assessment is 
complex and must consider the potentially disastrous consequences that could result from 
hypoglycaemia occurring underwater. Prospective observational studies have followed 
recreational divers with diabetes using detailed protocols for PGL management, 
suggesting that they can safely monitor and manage their PGL to allow diving.13-15 
However, it has never been determined if the potentially hazardous event encountered in 
hyperbaric medicine – the precipitous fall in PGL in a person with diabetes during HBOT 
– could also occur in response to the hyperbaric stimulus of the underwater environment. 
While other medical concerns will certainly exist for the potential diver with diabetes, this 
study provides the first evidence that exposure to a hyperbaric profile similar to that 
encountered in the recreational diving environment has no effect on insulin sensitivity.  
This encouraging finding may also be relevant to people in other hyperbaric 
environments. 
 
One limitation to these studies is that we have only investigated men. Insulin sensitivity 
can change physiologically in adolescence and during pregnancy and different parts of the 
menstrual cycle in women. However, our studies have demonstrated an insulin-sensitising 
effect of HBOT that is not limited to those with diabetes and is likely to be a metabolic 
response to HBOT. As such, we would expect to see the same effect in women although 
this has never been tested. Other limitations include the relatively small sample size. 
Despite this, the magnitude of the effect is large enough to achieve statistical significance 
and is comparable to previous studies. The already labour-intensive glucose clamp was 
made more complicated by performing it within a hyperbaric chamber. Our previous 
studies have allowed us to develop experience in the use of this technique in the 
hyperbaric environment. Strategies include keeping participants sedentary in reclining 
chairs and wheeling them, plus the infusions, into and out of the hyperbaric chamber to 
minimise exertion. The regular blood samples were passed out of the hyperbaric chamber 
through the medical lock for PGL analysis while the glucometer itself utilised a glucose 






This study has further strengthened the evidence that acute exposure to hyperbaric oxygen 
leads to a clinically significant increase in insulin sensitivity in men with type 2 diabetes. 
This effect is still evident during the first 30 minutes after exit from the hyperbaric 
chamber although its duration beyond that time is not known. Importantly, we have 
shown for the first time that this insulin-sensitising effect does not occur when breathing 
hyperbaric air at 2 atm abs (10 msw equivalent). This may be relevant to other hyperbaric 
environments such as recreational diving but further work would be required to 
definitively establish the absence of an effect when breathing air at greater depths. The 
insulin-sensitising effect requires the very high partial pressures of oxygen only 
encountered during clinical HBOT. Further research should be encouraged to discover the 
mechanism for this novel effect on metabolism, as it could translate to new clinical 
therapies to improve glucose regulation. 
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CONCLUSIONS AND RECOMMENDATIONS 
 
The hyperinsulinaemic euglycaemic glucose clamp has repeatedly identified a significant 
increase in peripheral insulin sensitivity during hyperbaric oxygen therapy (HBOT).1-4 
According to our studies, this effect comes on during the first HBOT intervention3 and 
persists for at least the first 30 minutes after HBOT2 although the duration is not known. 
The effect can be demonstrated in men without diabetes2, 3 which suggests that HBOT is 
activating physiological pathways and is not specific to people with diabetes. As such, 
further research is encouraged as identification of this pathway may lead to new 
therapeutic targets to improve glucose regulation. The glucose clamp is the gold standard 
for assessing insulin sensitivity however it was disappointing that the frequently sampled 
intravenous glucose tolerance test (FSIGT) technique failed to find any changes.3 In 
hindsight, there were a number of problems with the FSIGT and how it was used in the 
study and these issues may warrant revisiting, but it would be encouraging to demonstrate 
the insulin-sensitising effect of HBOT using alternative techniques of insulin sensitivity 
assessment. One technique to consider is the two-step glucose clamp using infusion of 
radioisotope-labelled glucose, which is a more complicated technique but would allow 
assessment of hepatic insulin sensitivity and the potential impact of an improvement in 
suppression of hepatic glucose production.  
 
The final glucose clamp study showed there was no change to insulin sensitivity when 
breathing hyperbaric air.4 The insulin-sensitising effect of HBOT requires both high 
inspired oxygen and increased pressure (2 atmospheres absolute), whereas breathing air at 
the equivalent of 10 metres sea water had no effect. This finding may be relevant to 
people in other hyperbaric environments such as diving. However, our simulated dive was 
relatively benign and further research is required to show that this effect is not activated 
by “deeper” diving profiles.   
 
The chronic low grade inflammatory state associated with the development of insulin 
resistance, diabetes and other medical conditions has been shown to involve inflammatory 
cytokine release from adipose tissue.5 Cytokines implicated in this pro-inflammatory 
process include TNF-α, MCP-1 and IL-6.6 Our studies and a review of the literature 
suggest HBOT has an inconsistent effect on inflammatory cytokine release. In fact, two 
of our studies which showed an insulin-sensitising effect of HBOT also showed an 
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increase in serum IL-6 after HBOT.2, 3 In one of these studies adipose tissue gene 
expression was measured and found no change in IL-6 expression in adipose tissue after 
HBOT.2 The role of IL-6 has become far more complicated than simply a pro-
inflammatory cytokine; consider the evidence that IL-6 is released from muscle during 
exercise,7 which is an insulin-sensitiser.8 It is possible that the increase in IL-6 after 
HBOT originates from skeletal muscle and this should be specifically investigated by 
techniques including muscle biopsy. However, changes to inflammatory cytokines may 
only be part of the story. Other pathways by which HBOT might influence insulin 
sensitivity and that deserve investigation involve oxidative stress mechanisms secondary 
to the high oxygen partial pressure. Enzymes within the intracellular insulin signalling 
pathway are very sensitive to reactive oxygen species with the effect to enhance insulin 
signalling.9 It has already been demonstrated that HBOT stimulates the release of stem 
cells from bone marrow via reactive oxygen species mediated pathways.10 The potential 
for HBOT to influence insulin sensitivity via oxidative stress mechanisms – the 
deliberated generation of reactive oxygen species – should be investigated by techniques 




• The evidence supports continuing research into the insulin-sensitising effect of 
HBOT. 
• The effect should be further defined by using alternative techniques for insulin 
sensitivity assessment, such as the two step glucose clamp with labelled glucose. 
• Specific future study aims should include: 
 Determining the duration of the effect. 
 Performing the study in women. 
• Dedicated “diving” studies testing more typical diving profiles should be 
undertaken to definitively show no change to insulin sensitivity in the diving 
environment. 
• Specific investigation for the mechanism of the insulin-sensitising effect of HBOT 
should include the origin and the role of the increase in serum IL-6 after HBOT by 
techniques including muscle biopsy. 
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• Other specific investigations should consider HBOT-initiated oxidative stress 
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